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Abstract
The

emergence

and

rapid

spread

of

multi-drug

resistant

(MDR)

Enterobacteriaceae is one of the most challenging problems we currently faced.
However, locally, no details on the strains causing outbreaks are available. Furthermore,
globally, we still do not understand what makes certain clones capable of spreading
widely while others are only confined to sporadic cases. Aim: Our aim was to
characterize the virulence factors, antibiotic and disinfectant susceptibilities of local
clonal and sporadic Escherichia coli and Klebsiella pneumoniae strains and to analyze
the data to reveal which particular feature might be responsible for the outbreak potential
of clonal isolates. Methods: Escherichia coli and Klebsiella pneumoniae strains
collected from countries of the Arabian Peninsula were subjected to genotyping by PCR
targeting a broad spectrum of virulence and antibiotic resistance genes. This was
followed by antibiotic susceptibility tests, serum resistance and biofilm formation assays
and molecular typing by macro-restriction analysis and multilocus sequence typing.
Results: Our study shows that among blood stream E. coli isolates, the rate of strains
expressing R4 core type is currently much higher than seen before, most likely due to a
few multi-resistant clones that have emerged recently. Further studies should reveal
whether, beyond their more extensive antimicrobial resistance, the presence of the
previously rare core types, or possibly the lower base-line immunity in the population
against them, contributes to their recent epidemiological success. We also show that a
majority of local K. pneumoniae clones do not possess considerably more virulencerelated features than sporadic isolates. Rather, they are clearly distinguishable from the
latter group by their broader spectrum of resistance to non-ß-lactam antibiotics, well
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substantiated by the increased carriage of the respective resistance genes. Resistance to
disinfectants was observed to be more common among K. pneumoniae strains nonsusceptible to carbapenems than among the antibiotic sensitive isolates. We speculate
that this may also increase the outbreak potential of the strains. Finally, we show that a
considerable part of local carbapenem resistant K. pneumoniae strains are still
susceptible to fosfomycin, although the rate of resistance to fosfomycin, particularly
among blood stream isolates, is already alarming. Conclusions: Together, data reveals
that it is particularly the increased resistance rather than any specific virulence-related
feature that makes strains spread as clones. A well-organized surveillance system based
on molecular typing is needed in the country to follow the characteristics of the spread
of multidrug resistance organisms in the region.

Keywords: Virulence factors, clonality, antibiotic and disinfectant resistance,
fosfomycin, Enterobacteriaceae.
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)Title and Abstract (in Arabic
انخصائص انجينيت نمعذل انضراوة و انتنسيم انجيني و انقذرة عهى مقاومت انمضاداث انحيىيت و انمطهراث
نهبكتيريا انمعىيت انمعزونت من شبت انجزيرة انعربيت

انمهخص

ٚشكم اَخشبس انبكخٛشٚب انًمبٔيت نهًعبداث انحٕٚٛت ٔ خبصت انبكخٛشٚب انًؼٕٚت انًمبٔيت نؼذد يٍ األدٔٚت () MDR
يٍ اكزش انخحذٚبث صؼٕبت ف ٙانٕلج انحبن ،ٙفؼهٗ انصؼٛذ انًحه ٙالحخٕفش أ٘ حفبصٛم ػٍ انسالالث انًسببت فٙ
حفش ٙاالٔبئت .أيب ػهٗ انصؼٛذ انؼبنً ٙفبَُب ال َسخطٛغ اٌ َفسش سبب لذسة بؼط انسالالث ػهٗ االَخشبسػهٗ َطبق
أسغ يٍ غٛشْب.

انٓذف :فْ ٙزا انبحذ سٛخى انخحمك يٍ خصبئص بكخٛشٚب Escherichia coli and Klebsiella pneumoniae
انخ ٙلذ حؼضص االَخشبس انُبصح نسالالث يؼُٛت دٌٔ االخشٖ أ٘ أٌ حظٓش حٕسغ َسٛه ٔ ،ٙسٛخى دساست رنك بخحذٚذ
خصبئص صُٛبث  virulence factorsببإلظبفت انٗ دساست لذسة ْزة انبكخٛشٚب ػهٗ يمبٔيت انًعبداث انحٕٚٛت
ببالظبفت نهًطٓشاث انًسخخذيت حبنٛب ٔ .بزنك سخسبْى ْزِ انذساست ػهٗ فٓى انؼٕايم انًؤدٚت الَخشبسسالالث يؼُٛت
دٌٔ غٛشْب.

انٕسبئم ٔ انطشق :نمذ حى صًغ يضًٕػبث يٍ بكخٛشٚب  Escherichia coli and Klebsiella pneumoniaeيٍ
دٔل شبّ انضضٚشة انؼشبٛت ٔ .خالل ْزِ انذساست اسخخذيج يضًٕػت ٔاسؼت يٍ انخمُٛبث انكالسٛكٛت ٔ انضضٚئٛت يزم
انبصًبث انضضٚئٛت بٕاسطت  MLSTنخحذٚذ انخُسٛم انض ُٙٛنهبكخٛشٚب  ٔ ،انخًُٛط انض ُٙٛبٕاسطت  PCRنخحذٚذ
انًسخٕٖ انض ُٙٛػهٗ َطبق أسغ ٔ رنك نٛشًم ححذٚذ خصبئص صُٛبث  ٔ virulence factorsصُٛبث انبكخٛشٚب
انًمبٔيت انًعبداث انحٕٚٛت  ٔ ،لذ حى اٚعب ححذٚذ يؼذل يمبٔيت انًصم ٔ يؼذل حشكٛم .biofilm

x

انُخبئش :اسخطؼُب اٌ َزبج اٌ َسبت بكخٛشٚب  Escherichia coliانًؼضٔنت يٍ يضشٖ انذو ححًم انُٕع انُبدس core
 ٔ type R4اٌ يؼذل ظٕٓسْب أػهٗ بكزٛش يٍ لبم ٔرنك لذ ٚشصغ انٗ ظٕٓسػذد يٍ انسالالث انًمبٔيت ف ٙأَٜت
األخٛشة ٔ ،نزنك ٚخٕصب اصشاء يضٚذا يٍ انذساسبث ٔ االبحبد نهكشف ػٍ سبب صٚبدة انًمبٔيت نذٓٚب ٔسبب ػٕدة
ظٕٓس االَٕاع انُبدسة يٍ  ٔ core typeيب ارا كبَج ْزِ انضٚبدة يشحبطت ببَخفبض يؼذل انًُبػت نالَٕاع انُبدسة
يٍ  core typeنذٖ انسكبٌ.

ٔ لذ اربخج انذساست اٚعب اٌ يؼظى انسالالث انًحهٛت نم  Klebsiella pneumoniaeال حًهك خصبئص حضٚذ يٍ
ظشأحٓب غٛش اٌ نٓب لذسة ٔاسؼت ػهٗ يمبٔيت االَٕاع االخشٖ يٍ انًعبداث انحٕٚٛت غٛش  ٔ ß-lactamرنك
الحخٕائٓب ػهٗ انضُٛبث انالصيت نزنك ٔ ،لذ اربخج انذساست اٚعب اٌ يؼذل انًمبٔيت نهًطٓشاث كبٌ اكزش شٕٛػب ػُذ
 Klebsiella pneumoniaeانًمبٔيت نم  carbapenemsيمبسَت يغ االَٕاع االخشٖ ٔنٓزا افخشظُب اٌ ْزا لذ
ٚسبْى ف ٙاَخشبس ْزِ انسالنّ انًمبٔيت دٌٔ غٛشْب ،ببالظبفت انٗ رنك فمذ اربخج انذساست اٌ بؼط يٍ Klebsiella
 pneumoniaeانًمبٔيت نم  carbapenemsيبصانج ػشظت نم  fosfomycinػهٗ انشغى يٍ اٌ يؼذل انًمبٔيت
نٓزة انسالنّ انًؼضٔنت يٍ يضشٖ انذو ٚؼخبش ػبنٛب ٔ ٚؼذ يؤششا نهخطش.

االسخُخبس :حشٛش انبٛبَبث انًخٕفشة نذُٚب اٌ انضٚبدة ف ٙيؼذل انًمبٔيت نهبكخٛشٚب نٛس يشحبطب بخصبئص يؼُٛت يٍ
صُٛبث ْ ٔ virulence factorsزا لذ ػضص بذٔسِ االَخشبس انُبصح نسالالث يؼُٛت دٌٔ االخشَٖ ٔ ،أيم أٌ ْزِ
انذساست سخسبػذ ف ٙسٍ انخذابٛشانٕلبئٛت كخأسٛس َظبو يشالبت صٛذ ف ٙانذٔنت لبئى ػهٗ انخحهٛم انضضٚئ ٙنًخببؼت
خصبئص اَخشبس انبكخٛشٚب انًمبٔيت نؼذد يٍ األدٔٚت ( ) MDRفْ ٙزِ انًُطمت.

مفاهيم انبحث انرئيست :يؼذل انعشأة ،انسالالث انبكخٛشٚت  ،يمبٔيت انًعبداث انحٕٚٛت ٔ انًطٓشاث ،
انفٕسفبيبٚسٍ ،انبكخٛشٚب انًؼٕٚت.
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Chapter 1: Introduction
The problem of antibiotic resistance is one of the most significant challenges we
face today. Only 70 years after the discovery of the first antimicrobial agent, the
possibility of losing these, once considered "miracle" drugs, is a reality (Gootz, 2010).
The problem affects practically any drug and species, but due to their complex cell wall
structure, it is most threatening among Gram-negative bacteria (Walsh and Toleman,
2012). Regretfully, there are few, if any, promising new drugs in the research/production
pipelines. Hence, the recent warning of the WHO, i.e., that this trend is to "...reverse
medical progress...", is not unrealistic (WHO, 2000).

ß-lactam drugs occupy a special niche among antibiotics. Beyond the relative
ease of dosing them and their usually good, or acceptable tissue distribution, they act on
a target, i.e. the cell wall, which we, their hosts, do not have. Hence, compared to other
antibiotics, they are relatively safe. Consequently, emerging resistance to this group is
probably the most painful development (Gootz, 2010; Martinez et al., 2009; WHO,
2000)

After

resistance

started

emerging

to

simple

ß-lactams

(penicillins,

aminopenicillins, 1st and 2nd generation cephalosporins) and concomitantly to other
agents (e.g. tetracyclines, sulfonamids, quinolones, etc.) (Gootz, 2010; Martinez et al.,
2009; WHO, 2000), at least for a while, 3rd and 4th generation cephalosporins offered a
solution, and in selected cases, they still can be used to treat life-threatening infections.
But with the rapid emergence of extended spectrum ß-lactamase (ESBL) enzymes
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combined with the often clonal spread of strains carrying them, we face a new problem
(Stokes and Gillings, 2011). Furthermore, it was before long that the problem spilled out
from hospitals to the community and nowadays ESBL producing Escherichia coli or
Klebsiella pneumoniae isolates acquired in the community are very common (Martinez
et al., 2009). All these developments gradually lead to the increased use of carbapenems,
i.e., the "ultimate" ß-lactam antibiotics. As predicted, resistance to these drugs also
became more and more common leaving only "far from ideal" drugs, e.g. tigecycline or
colistin in the armory (Falagas et al., 2005; Xu et al., 2013).

One way of spreading resistance relates to the spread of resistant bacteria, i.e.,
colonizing, infecting one susceptible host after the other. Beyond that, however, as
antibiotic resistance genes are frequently located on plasmids, i.e., on mobile genetic
elements, they can also spread from cell to cell, often not even respecting species
boundaries. Finally, as a third level of its spread, resistance genes are not infrequently
linked to genetic structures capable of relocating within the genome, i.e., transposons,
integrons etc., (Stokes and Gillings, 2011).

The fact that spreading of resistant strains strongly depends on the fitness and/or
virulence of the microbial cell raises important questions: what are the fitness-, and
virulence-related factors of highly resistant bacteria? In my thesis, I have tried to answer
this question by focusing on a unique group of such pathogens, i.e., carbapenem resistant
Klebsiella pneumoniae a group of strains probably representing the most serious current
threat to our hospitals. I have also studied the respective factors and genes of
Escherichia coli strains isolated exclusively from blood, focusing particularly on the
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possible effects of deep cell wall structures on the emergence of some of the globally
spreading clones.

The presence of antibiotics clearly represents a strong pressure towards selecting
drug resistant variants. However, antibiotics are not the only agent bacteria are exposed
to in hospitals, in the community and increasingly, in the environment, as well (Gilbert
and McBain, 2003). Biocides and disinfectants are usually applied in extremely high
concentrations, but by distance and with time they lose their activity, and bacteria with
decreased susceptibility to some of these agents may have an advantage over others to
survive (Maillard, 2002; Russell, 2002). This decreased susceptibility is usually the
result of increased expression of the so-called multidrug resistance efflux pumps
expelling various toxic substances from the cell. However, as they often also expel
antibiotics, they may also cause resistance to those compounds (Levy, 2002b). In
another part of my thesis, I have studied whether resistance to antibiotics relates to
decreased susceptibility to disinfecting agents.

With the decreasing efficacy of our standard antibiotics, alternative drugs are
needed. Theoretically, they could be new ones (and we are very short of those), but also
older ones, that have not been used extensively so far to treat serious infections. One of
these agents is fosfomycin. Therefore, in the last part of my thesis, I have studied the
fosfomycin susceptibility of local carbapenem resistant isolates.

With this work, my intention was to provide a humble contribution to a better
understanding of the complex mechanism of the spread of antibiotic resistance. I would
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like to hope that the results will help, even if to a small extent only, to improve our
actions to control the problem.
1.1 Antibiotics

Antibiotics, a group of antimicrobial agents, are produced by microorganisms, albeit
some are currently synthetized chemically for mass-production or the original structure
is chemically modified to increase efficacy and/or improve pharmacological features.
Antibiotics have well-defined modes of action with more or less restricted spectrum of
bacterial species they are effective against (Forbes et al., 2002; Greenwood et al., 2007).
The effect of antibiotics can be bacteriostatic or bactericidal, the result depends on the
drug and species, and in some cases on the concentration. They are grouped by their
mode of action and, within the same action-groups, by their chemical structure. The
main modes of action with examples are shown in Table 1. (Tortora et al., 2013; Willey
et al., 2008).

Table 1: Main mode of action of antibiotics
Mode of action

Examples

Inhibition of cell wall synthesis
Inhibition of protein synthesis

ß-lactams, Glycopeptides, Fosfomycin
Aminoglycosides, Macrolides, Tetracyclines,
Chloramphenicol
Quinolones, Fluoroquinolones, Rifampin

Interference with nucleic acid
synthesis
Cell membrane disruption
Antimetabolites

Polymyxins
Sulfonamides, Trimethoprim

The majority of my thesis work has focused on bacteria resistant to ß-lactam
antibiotics and fosfomycin, so I will focus on these two groups.
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1.1.1 ß-Lactam Antibiotics

Members of this group includes penicillins, cephalosporins, monobactams and
carbapenems. To all, a unique structure, the ß-lactam ring is characteristics. The
structures of the main ß-lactam groups are shown on Figure 1. All act in the same way,
i.e., by inhibiting cell wall synthesis. Due to the variations in their molecular structure,
they have different chemical properties and spectrums of activity. (Harvey et al., 2007;
Willey et al., 2008)

Figure 1: Chemical structure of the main β-lactams
(Nordmann et al., 2012a).
These drugs interfere with the transpeptidase enzymes (called Penicillin Binding
Proteins, PBPs) involved in the synthesis of the peptidoglycan molecule, i.e., the key
structural component of the cell wall (Kong et al., 2010; Scheffers and Pinho, 2005).
Bacterial species may contain between four to six different types of PBP involved in cell
wall cross-linking. The synthesis of the cell wall, i.e., the structure necessary to resist
high intracellular osmotic pressure, stops upon the drugs‘ interference with PBPs and the
cell lyses. Consequently, ß-lactam drugs are bactericidal to almost all species that are
susceptible to them (Forbes et al., 2002; Harvey et al., 2007).
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1.1.1.1 Penicillins

Penicillins can be classified into four main groups according to their spectrum of
activity and structure. In the first group are natural penicillins (Penicillin G and
Penicillin V). They are effective against non-ß-lactamase producing Gram-positive
aerobic organisms, including Streptococcus, against anaerobs like Clostridium spp., and
against some Gram-negative bacteria like Neisseria meningitidis. With the exception of
a few species, extensive resistance has developed in most organisms against these agents
(Murray et al., 2012; Willey et al., 2008). The second group is made of penicillinase
resistant penicillins (oxacillin, cloxacillin, dicloxacillin, methicillin and nafcillin). They
are effective against Staphylococcus spp. that produce ß-lactamase (penicillinase).
Aminopenicillins (ampicillin, amoxicillin, bacampicillin) belong to the third group.
Their spectrum is extended towards Gram-negative organisms like Haemophilus
influenzae, E. coli and Proteus mirabilis. Extended spectrum penicillins (carbenicillin,
ticarcillin, mezlocillin and piperacillin), also known as anti-pseudomonas penicillins,
form the fourth group. They have increased activity against Gram-negative organisms
including Pseudomonas spp., Enterobacter spp., and Proteus spp. (Doi and Chambers,
2015; Murray et al., 2012; Willey et al., 2008)

1.1.1.2 Cephalosporins

Cephalosporins are classified into five generations on the basis of their spectrum
of activity and resistance to various ß-lactamases.

First generation agents (e.g.,

cephalexin, cefalotin and cefazolin) are active primarily against Gram-positive
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organisms, including methicillin sensitive S. aureus and have limited activity against
Gram-negative bacilli. Second generation agents (e.g., cefaclor, cefuroxime and
cefoxitin) have increased activity against Gram-negative bacilli and variable activity
against Gram-positive cocci. Third generation agents (e.g., ceftazidime, cefotaxime and
ceftriaxone) exhibit significantly increased activity against Gram-negative bacilli. The
fourth generation drugs (e.g., cefepime) have further increased their spectrum of activity
against both Gram-positive and Gram-negative bacteria (Murray et al., 2012; Willey et
al., 2008). Members of the relatively recent fifth generation (e.g., ceftaroline) have
increased affinity even to altered PBPs, particularly to PBP2a, i.e., the mutated version
of the protein present in methicillin resistant Staphylococcus aureus (MRSA); hence, it
is the only ß-lactam effective against this group of pathogens (Craig and Andes, 2015;
Harvey et al., 2007; Murray et al., 2012). The 3rd and 4th generation cephalosporins
continued to be the ß-lactam drugs to be used in life-threatening infections despite the
emergence of extensive resistance over the last few years. (Cole et al., 2015; Dancer,
2001; Lee et al., 2015).
1.1.1.3 Monobactams

Monobactams (e.g. aztreonam) are bactericidal antibiotics with a spectrum that is
restricted to aerobic Gram-negative bacteria (Forbes et al., 2002; Willey et al., 2008).
1.1.1.4 Carbapenems

Carbapenems have a structure that renders them highly resistant to ß-lactamases.
They are active against most Gram-positive and Gram-negative aerobic and anaerobic
bacteria. The four most commonly used carbapenems are imipenem, meropenem
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ertapenem and doripenem. Imipenem is used along with the inhibitor cilastatin to
prevent its metabolism by the renal dehydropeptidases (DHP-1). Unlike meropenem,
imipenem is more active against Gram-positive than Gram-negative bacteria.
Meropenem demonstrats a long half-life with higher blood levels and therefore does not
require the co-administration of cilastatin (Murray et al., 2012; Willey et al., 2008).
Ertapenem is not active against non-fermenting organisms like Acinetobacter and
Pseudomonas; therefore it is not used in nosocomial infections without a known
etiology. Doripenem is a newly approved carbapenem with a broad spectrum coverage
and anti-pseudomonal activity and is used for the treatment of serious nosocomial
infections including ventilator associated pneumonia. Today carbapenems are the
ultimate ß-lactam drugs, particularly in the treatment of severe Gram-negative infections
(Falagas et al., 2014; Hawkey and Livermore, 2012; McLaughlin et al., 2013; PappWallace et al., 2011; Zhanel et al., 2007).

1.1.2 Fosfomycin

Fosfomycin was initially isolated in 1969 from cultures of Streptomyces fradiae,
although it can now be produced by chemical synthesis. There are three forms of
fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral
use, and fosfomycin disodium for intravenous use (Karageorgopoulos et al., 2011).

Fosfomycin has a unique mechanism of action and is often synergistic with other
classes of antibiotics, including ß-lactams, aminoglycosides and fluoroquinolones. It is
bactericidal and inhibits the bacterial cell wall biogenesis by inactivating the enzyme
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UDP-N-acetylglucosamine-3-enolpyruvyltransferase, also known as MurA. During
peptidoglycan biosynthesis, this enzyme catalyzes the ligation of phosphoenolpyruvate
(PEP) to the 3'-hydroxyl group of UDP-N-acetylglucosamine. This pyruvate moiety
provides the linker that bridges the glycan and peptide portion of peptidoglycan.
Fosfomycin is a PEP analog that inhibits MurA by alkylating an active site cysteine
residue (Cys 115 in the Escherichia coli enzyme) (Karageorgopoulos et al., 2011;
Michalopoulos et al., 2011).

Fosfomycin has broad antibacterial activity, covering both Gram-positive and
Gram-negative pathogens, and has an excellent activity against extended spectrum βlactamase (ESBL) producing pathogens, notably against E. coli and K. pneumoniae.
Lately, it is increasingly mentioned as a ―rescue drug‖ for infections due to carbapenem
resistant organisms. Although development of bacterial resistance during therapy has
been documented, little is known about the rate of resistance among MDR Gramnegative bacteria (Falagas et al., 2008; Neuner et al., 2012; Senol et al., 2010).

1.2 Resistance to Antibiotics

Resistance to antimicrobial treatment, in a broad sense, can be attributed to
several cellular and non-cellular factors. Examples of situations in the latter group are
when, the antibiotics cannot reach an otherwise susceptible cell in sufficiently high
concentration because of its location (e.g. bone tissues, prostate or the central nervous
system) or unique growth pattern (e.g. biofilms). Although these situation can lead to
unsuccessful antibiotic treatment, i.e., resistance to therapy, they are not considered to be
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cases of antibiotic resistance, per se¸ since resistance derives from the native (intrinsic),
or acquired features of the microbial cell.(Blair et al., 2015; Chen et al., 2009; Davies
and Davies, 2010; Opal and Pop-Vicas, 2015).

Intrinsic resistance is a type of antibiotics resistance that result from the normal,
standard, wild type genetic, structural or physiologic features of a microorganism. It is
associated with a majority strains that represent a particular taxonomical entity, group,
genus or species. Consequently, when such a particular strain is isolated, these aspect of
its antibiotic resistance profile are predictable, for as observed with e.g., ertapenem
resistance of non-fermenting Gram-negative rods (Forbes et al., 2002; Opal and PopVicas, 2015).

Acquired resistance, on the other hand, results from alterations in the wild type
genetic make-up of a microorganism. This type of resistance is associated with particular
strains of a given taxonomical entity only (e.g., meropenem resistance of non-fermenting
Gram-negative rods). Consequently, the presence of this acquired resistance is not
predictable based on taxonomy. This type of resistance can be acquired by:


a mutation



horizontal gene transfer, i.e., uptake and successful expression of new
genetic material into the genome of the cell

(Alekshun and Levy, 2007; Forbes et al., 2002; Magiorakos et al., 2012)
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1.2.1 Mechanisms of Antibiotic Resistance

Bacteria share some common strategies leading to resistance to antibiotics
irrespective of whether the resistance is intrinsic or acquired. Sometimes, multiple
mechanisms, affecting the same group of antibiotics are required to achieve clinically
relevant decrease in susceptibility (e.g., a reduction in intracellular concentration of the
drug combined with the production of a moderately effective hydrolyzing enzyme
(Dever and Dermody, 1991; Harvey et al., 2007; Murray et al., 2012). On the other
hand, not infrequently, multiple mechanisms sufficiently effective on their own may be
present in the same cell providing an apparent redundancy in achieving resistance (e.g.,
the presence of multiple carbapenemases) (Arnold et al., 2011; Bush, 2013; Opal and
Pop-Vicas, 2015). Quite commonly, multiple mechanisms affecting different groups of
antibiotics co-expressing in the same cell lead to MDR (Alekshun and Levy, 2007;
Nikaido, 2009; Tortora et al., 2013). The most common mechanisms of antibiotic
resistance are as follows (Blair et al., 2015; Lin et al., 2015; Shaikh et al., 2015):


producing enzymes that destroys the antibiotic



altering antibiotic‘s target molecule (while preserving its functionality).



reducing the drugs uptake



increasing efflux of the compound



molecular shielding of the antibiotic‘s target resulting in preventing proper
access of the antibiotic molecule



By-passing the metabolic steps the antibiotic is supposed to interfere with
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Bacteria are often increasingly resistant to multiple antibiotics, representing an
increased threat to health-care both in the community, as well as in the hospitals.
Recently, the Centers for Disease Control and Prevention (CDC), USA have identified
those organism which represent the most urgent threats of antibiotic resistance (Table 2.)
(CDC, 2013)
Table 2: Categories of urgent threats of antibiotic resistant bacteria
Clostridium difficile
Carbapenem-resistant Enterobacteriaceae (CRE)
Drug-resistant Neisseria gonorrheae
Multidrug-resistant Acinetobacter
Drug-resistant Campylobacter
Fluconazole-resistant Candida (a fungus)
Extended spectrum β-lactamase producing Enterobacteriaceae
(ESBLs)
Vancomycin-resistant Enterococcus (VRE)
Multidrug-resistant Pseudomonas aeruginosa
Drug-resistant non-typhoidal Salmonella
Drug-resistant Salmonella Typhi
Drug-resistant Shigella
Methicillin-resistant Staphylococcus aureus (MRSA)
Drug-resistant Streptococcus pneumoniae
Drug-resistant tuberculosis
Vancomycin-resistant Staphylococcus aureus (VRSA)
Erythromycin-resistant Group A Streptococcus
Clindamycin-resistant Group B Streptococcus

Urgent
threats

Serious
threats

Concerning
threats

1.3 Resistance to ß-Lactam Antibiotics
Bacterial resistance to β-lactams can be mediated by:


altering the target of the drugs



decreasing the intracellular concentration of the compound



enzymatic destruction of the antibiotics
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1.3.1 Target Alteration

The first mechanism is common and highly effective in Gram-positive bacteria
(e.g., in methicillin resistant Staphylococcus aureus, MRSA or in Streptoccoccus
pneumoniae), and is also present in some Gram-negative organisms (e.g., the ßlactamase negative, ampicillin resistant (BLNAR) strains of Haemophilus influenzae
(Dever and Dermody, 1991; Lambert, 2005; Tristram et al., 2007).

However, in

converting Enterobacteriaceae to ß-lactam resistant, it has limited, if any role; hence it
will not be discussed here.

1.3.2 Decreasing Intracellular Concentration

The intracellular concentration of a drug can be limited in two ways either by
expelling molecules already taken up or by limiting their uptake. The first mechanism is
usually achieved by the up-regulation of the expression of efflux pumps (Poole, 2005;
Webber and Piddock, 2003). These efflux pumps vary in the spectrum of compounds
they are able to expel from the cell, but often they are multi-drug efflux pumps
(Aeschlimann, 2003; Rouveix, 2007; Sun et al., 2014). Although this spectrum may
include various ß-lactam drugs in Enterobacteriaceae, in their cephalosporin and
carbapenem resistance efflux pumps, play a comparatively minor role, seldom leading to
clinically significant level of resistance to these agents (Andersen et al., 2015; Pages et
al., 2009).

The other mechanism is the modification of porins in the outer membrane
resulting in limited uptake of the drugs. This mechanism has considerable effectiveness
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in Enterobacteriaceae, by lowering the susceptibility to cephalosporins and
carbapenems (Pages et al., 2008; Wozniak et al., 2012) are porin loss (Yang et al.,
2010), narrowing channel of porins (Nikaido, 1989), and decreasing expression of porin
(Doumith et al., 2009) the three distinct strategies of porin modification to limit the
carbapenem uptake in Enterobacteriaceae (Pages et al., 2008). If alone, uptake
restriction due to porin loss may not result in clinically significant loss of susceptibility;
however, once, combined with the production of hydrolytic enzymes, even with limited
carbapenemase activity on their own (see later), the combined effect of these two
mechanisms can cause clinically significant carbapenem resistance.

1.3.3 Enzymatic Degradation of ß-Lactams
Enzymatic inactivation of β-lactam agents is the most common and most
effective resistance mechanism among Enterobacteriaceae against this group of
antibiotics (Forbes et al., 2002; Murray et al., 2012).

Two classification schemes for ß-lactamases are currently in use (Bush and
Jacoby 2010). The Ambler molecular system, based on conserved and distinguishing
amino acid motifs, classifies ß-lactamases into four molecular classes, i.e., A, B, C, and
D (Table 3 - see page 18). On the other hand, grouping by the Bush-Jacoby-Medeiros
system is based on the functional similarities (including substrate spectrum and
susceptibility to inhibitors, such as clavulanic acid, sulbactam and tazobactam) of the
various enzymes forming four main, and multiple subgroups (Table 3.) (Ambler, 1980;
Bush and Jacoby, 2010; Hall and Barlow, 2005).
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The highest number of ß-lactamases are found in Ambler molecular class A.
They can characteristically be inhibited by ß-lactamase inhibitors. Their genes are often
located on plasmids; therefore, they have the ability to spread among members of the
same species or even among different genera. The best known representatives of this
group are Temoneira (TEM) and Sulfhydryl reagent variable enzyme (SHV) type
enzymes. The original molecules had relatively narrow substrate spectrum. However,
subsequent mutations have resulted in considerable extension of their spectrum,
including 3rd and 4th generation cephalosporins (and in some cases a low activity also
against carbapenems). Enzymes with such extended spectrum are called extended
spectrum ß-lactamases (ESBLs) (Fong and Drlica, 2003; Harvey et al., 2007; Rupp and
Fey, 2003).

Beyond the TEM and SHV-type ESBLs, there are several other groups of such
enzymes. Currently, the Cefotaximase (CTX-M) type of ESBLs, with characteristically
high activity against cefotaxime, represents a new and rapidly growing family of
molecular class A ESBLs. They have five distinct phylogenetic groups and several types
have been described. In recent years, the CTX-M type ESBLs are now actually the most
frequent ESBL type worldwide (Bonnet, 2004; Cantón et al., 2008; Eisner et al., 2006;
Zowawi et al., 2013)

Other important members of this group are the enzymes with an even further
extended activity spectrum, i.e., carbapenemases. An important example is the K.
pneumoniae carbapenemase (KPC), first detected in USA in 1996, that is currently the
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most common carbapenemase in several parts of the world (Arnold et al., 2011;
Nordmann et al., 2009; Sonnevend et al., 2015a; Won et al., 2011; Zowawi et al., 2014).

Molecular class B enzymes are the so-called Metallo ß-lactamases (MBL) that
require a divalent cation for their activity and hence, can be inactivated by chelators,
such as EDTA or dipicolinic acid (DPA). There are several broad spectrum enzymes
among them with activity against all ß-lactams (including carbapenems) with the
exception of monobactams. Similar to group A enzymes, their genes can often be found
on mobile genetic elements. They are commonly present in non-fermenting bacteria,
such as Pseudomonas and Acinetobacter¸ but are spreading fast in Enterobacteriaceae.
Examples of these enzymes are the Verona integron-encoded metallo-β-lactamase
(VIM), Imipenem Metallo ß-lactamases (IMP) and the recently emerging New Delhi
Metallo ß-lactamases (NDM) (Cornaglia et al., 2011; Ghazawi et al., 2012; Sonnevend
et al., 2012; Walsh and Toleman, 2012).

The most important types of class C enzymes are the AmpC-type enzymes.
Some, if hyper-expressed, have broad spectrum activity which includes hydrolysis of 3rd
and 4th generation cephalosporins, and in some cases, have even a weal to moderate
activity against carbapenems. In some species, the over expression of the ß-lactamase to
achieve clinical resistance is inducible by ß-lactam drugs, while in others they are
constitutively expressed (Hanson, 2003; Jacoby, 2009; Thomson, 2010).

Molecular class D enzymes are primarily oxacillinases (OXA) that vary in their
spectrum considerably. An important group even has carbapenemase activity, although
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some of these enzymes exhibit simultaneously no or moderate activity against
cephalosporins (Evans and Amyes, 2014; Walther-Rasmussen and Høiby, 2006). They
predominantly occur in various non-fermenting Gram-negative rods, but currently are
fast spreading in Enterobacteriaceae.(Ahn et al., 2015; Cantón et al., 2012).
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Table 3: Classification of β-lactamases
(Bush and Jacoby, 2010; Bush et al., 1995)
Molecular
class

BushJacobyMedeiros

Active
site

2a
2b
2be
2br
2c
2e
2f

Serine

B

3

Zn2+

C

1
1e

Serine

A

Enzyme type

Not
Determined

2d

4

Inhibitors

Gene
Location

Aminopenicillins

TEM1
SHV1

Clavulanic
acid

Plasmid
Chromosome

Extended Spectrum ßlactamases (ESBL)

Broad spectrum and
aztroneam

TEM-derived,
CTX- derived

Clavulanic
acid

Plasmid

Carbapenemases

Extended spectrum plus
cephamycins

KPC-2
KPC-3

Clavulanic
acid

Chromosome

Metallo-β-lactamases

Extended spectrum plus
cephamycins
Extended spectrum plus
cephamycins
Cloxacillin, methicillin

IMP,VIM, GIM,
NDM
AmpC-type

EDTA

OXA-family in
P. aeruginosa

Cloxacillin
Monobactam
Clavulanic
acid +/-

Plasmid
Chromosome
Plasmid
Chromosome
Plasmid
Chromosome

Extended spectrum

Broad spectrum and
monobactams

OXA-derived in
P. aeruginosa

Clavulanic
acid +/-

Plasmid
Chromosome

Carbapenemases

Extended spectrum plus
cephamycins

OXA-derived in
Acinetobacter

Clavulanic
acid +/-

Plasmid
Chromosome

Penicillinase from
Pseudomonas
cepacia

Penicillins

Not available

Clavulanic
acid –
EDTA

Not available

Cephalosporinases

Serine

Not
available

Examples

Penicillinases
Broad Spectrum

Oxacillinases
Broad spectrum

D

Substrates
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1.4 Fosfomycin Resistance
Bacteria use several mechanisms to resist fosfomycin, including decreasing drug
uptake, modification of the target site, and inactivation of the antibiotic (CastañedaGarcía et al., 2013; Karageorgopoulos et al., 2011). There are two main fosfomycin
transport systems in E. coli involving the glycerol-3-phosphate transporter (GlpT) and a
hexose phosphate transporter (UhpT), respectively. Any mutations affecting either of
these transporters can result in fosfomycin resistance. The GlpT transporter is
constitutively expressed, while the UhpT is inducible, mainly in the presence of glucose6-phosphate (Cordaro et al., 1976; Huang et al., 2003).

Modification of MurA, the target of the drug‘s action (Karageorgopoulos et al.,
2011), and overexpression of MurA (Horii et al., 1999) are also causing resistance to
fosfomycin. These mechanisms have been reported in E. coli, Vibrio fischeri,
Mycobacterium tuberculosis and Chlamydia trachomatis (Kumar et al., 2009; Nilsson et
al., 2003; Takahata et al., 2010)

Presence of specific genes can contribute to the development of resistance to
fosfomycin. Three main genes have been described in pathogenic bacteria like fosA,
fosB and fosX (Arca et al., 1988; Leon et al., 1985; Suárez and Mendoza, 1991). The
fosA and fosB genes are typically found in plasmids of Gram-negative and Grampositive bacteria, respectively, while fosX is a chromosomal enzyme of Listeria
monocytogenes. Novel resistance determinants that mediate transferable resistance to
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fosfomycin through inactivation of the antibiotic have also been described (Ho et al.,
2013; Lee et al., 2012; Wachino et al., 2010)

1.5 Disinfectants and Disinfectant Resistance
Antibiotics are not the only agents with anti-microbial activity. Disinfectants and
antiseptics are biocides, i.e., chemical substances acting on a broad variety of species.
Disinfectants are applied on non-living surfaces, while antiseptics are used on live
tissues to reduce the number, or in some cases, eliminate infecting microorganisms
(McDonnell and Russell, 1999; Russell, 2002).

Biocides are commonly used in medicine, agriculture, forestry and industry.
However, the overuse or improper storage of the formulations lead to the development
of resistance to biocides due to decrease in the effective concentration (Chapman, 1998;
Poole, 2002). This phenomenon has been reported and published since 1950s,
particularly with the contamination of cationic biocide formulations (Chapman, 2003a;
Russell, 2002).

Biocides have been classified into four main groups with multiple subgroups
(AccuStandard, 2014; EU, 2012): 1. Disinfectants and general biocidal products, 2.
Preservatives, 3. Pest control agents and 4. Other biocidal products. Agents which are of
prime importance in infection control belong to group 1.

The quaternary ammonium compounds (QACs) like benzalkonium chloride
(BENZ), cetylpyridinium chloride, cetrimide, proceine and detizor are routinely used in
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both clinical and industrial settings, like disinfecting food-processing and production
environments, in order to prevent the spread of pathogens (Russell, 2000; Sidhu et al.,
2002; Sidhu et al., 2001). Consequently, it has been suggested that QACs can play a role
in promoting the development of antimicrobial resistance by co- or cross-resistance to
antimicrobials (Chapman, 2003b).

The mechanisms of action of the biocide depends on the bacterial structure that
biocides interact with. Accordingly, three levels of interaction can be described: (i)
interaction with outer cellular components, (ii) interaction with the cytoplasmic
membrane, and (iii) interaction with cytoplasmic constituents (Busta et al., 2006).

Intrinsic and acquired are two main mechanisms have been developed by
bacteria to resist biocides. The first mechanism is intrinsic (inhered by bacterium) that
include change in permeability, efflux pumps, degradation and modification of target
sites. On the other hand, acquired (mutations or acquisition of mobile genetic elements)
is the second mechanism. In both mechanisms, the concentration of intracellular of
biocides are decreased to an extent that they lose effectiveness (Busta et al., 2006).
There are some factors affecting biocides activity, notably concentration, period of
contact, pH, temperature, the type, nature and numbers of microorganisms to be
inactivated, and the presence of organic or other interfering materials (Chapman, 2003a;
Cloete, 2003; Russell, 2002).

Bacteria may become resistant to all known biocides (Chapman, 1998). In the
health care setting, bacterial resistance to biocides has long been reported with
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compounds such as: chlorhexidine (Stickler, 1974); quaternary ammonium compounds
(Gillespie et al., 1986); bisphenol triclosan (Schmid and Kaplan, 2004); iodophor
(Anderson, 1989); parabens (Flores et al., 1997; Valkova et al., 2001) ; and more active
biocides such as glutaraldehyde (Vikram et al., 2015) and peroxygens (Eissa et al.,
2014). While biocides are effective against planktonic populations of bacteria, they
could be ineffective against nosocomial pathogens growing in biofilms (Otter et al.,
2015).

Regarding the most common efflux-related biocid resistance genes, sugE(c),
emrE, ydgE/ydgF and mdfA are chromosomally encoded QAC resistance genes (Bay
and Turner, 2009; Edgar and Bibi, 1997; Zou et al., 2014). The mdfA belongs to the
major facilitator superfamily (MFS) of efflux pumps, while sugE(c) ,emrE and
ydgE/ydgF are members of the small multidrug resistance (SMR) family. Additionally,
five QAC resistance genes qacE, qacED1, qacF, qacG and sugE(p) have been identified
on mobile genetic elements, e.g., on plasmids or on integrons, in Gram-negative
organisms. They belong to the SMR family conferring efflux-mediated resistance to
QACs (Bay et al., 2008; K ücken et al., 2000; Russell, 1997; Zou et al., 2014).

It has been suggested that biocide and antibiotic resistance in bacteria might be
linked by three main principles (Chapman, 2003a):

1. Cross-resistance: genes that are encoding for resistance to both biocides and one
or more antibiotic classes. This resistance can involve efflux pumps (Levy,
2002a), changes in cell envelope that includes reduction or changes in porins,
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LPS and other lipids (Denyer and Maillard, 2002), and finally, production of
biofilm (SCENIHR, 2009).

2. Co-resistance: genes encoding resistance or reduced susceptibility. These genes
conferring resistance are presented on the same extra-chromosomal element,
integrons, transposons or plasmids are transferred and expressed jointly in a new
bacteria. For example, the qac-genes are often together with sul1 genes encoding
sulphonamide resistance located as part of mobile genetic elements, which can
also harbor various other resistance genes (Sidhu et al., 2002; Sidhu et al., 2001).
This observation is similar to what other investigators have found. For example,
a similar distribution of three qac resistance genes have been observed in clinical
S. aureus and Coagulase-negative staphylococci (CNS) (Mayer et al., 2001).

3. Enhanced DNA repair, e.g., by activating SOS response in bacteria, which
promotes horizontal gene transfer of resistance genes (Maiques et al., 2006;
Úbeda et al., 2005)

1.6 The Spread of Resistance
The spread of resistance is a highly complex phenomenon. It takes place at two
distinct levels: at the level of the microorganism, and at the level of the niches providing
an environment sustaining resistant cells. On the former level, on one hand, it includes
the re-location of resistance gene-containing genetic elements, such as genomic islands,
transposons, gene cassettes and integrons between various parts of the genome within
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the cells (Forbes et al., 2002; Normark and Normark, 2002).

On the other hand

resistance genes pass across cellular, often even across species borders, by horizontal
gene transfer via transduction, conjugation and transformation (Gyles and Boerlin, 2014;
Harvey et al., 2007). The combination of these mechanisms allows, as often has been the
case for ß-lactamases, that resistance genes originally evolved in environmental bacteria
eventually reaching human pathogens (Alekshun and Levy, 2007; Blair et al., 2015;
Stokes and Gillings, 2011).

The other level of spread of resistance takes place at the level of the
environment, defined in a broader sense i.e., as the inanimate environment, as well as the
host. This means the capacity of the strain to survive in and spread between susceptible,
permissive niches, inanimate or alive. It requires the delicate interaction between the
microorganism and the particular niche. The latter one should provide conditions to
sustain the microbe, i.e., it should be susceptible to be colonized by the particular strain.

1.7 Fitness, Pathogenicity and Virulence
The microbe should be fit enough to take the chances offered by a given
environment, i.e., it should be fit enough to face the challenges. Importantly, if the niche
also provides selective advantage to the resistant cells, e.g., it contains the antibiotic to
which certain cells of the population are more resistant to than others, their rate in the
population increases to the level of being exclusive. (Forbes et al., 2002; Harvey et al.,
2007; Murray et al., 2012). Fitness is the capacity of a microorganism to maintain itself
in a permissive environment either inanimate or alive. Pathogenicity is the capacity to be
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maintained in a susceptible living host of a specific species in a way that is harmful to
the latter organism. The extent of this capacity is expressed by the quantitative term
―virulence‖ and its extent is determined by the presence, variety, and expression of
specific microbial factors (i.e. ―virulence factors‖) needed for these specific parasitehost interactions. The concept is summarized in Figure 2.

Figure 2: An overview of bacterial mechanisms of pathogenicity
(Tortora et al., 2013).

Within a species there could be specific phylogenetic lineages with uneven
distribution of virulence factors among them making one lineage more likely to be
pathogenic than others. This is particularly well studied in E. coli. In 2000, a triplex PCR
was developed to identify the major phylogenetic groups (A, B1, B2 and D) of this
species (Clermont et al., 2000), which was further refined recently (Doumith et al.,
2012). The majority of E. coli strains causing extraintestinal infections (Extraintestinal
Pathogenic E. coli, ExPEC) belong to phylogroup B2, and, less commonly, to
phylogroup D (Dale and Woodford, 2015).
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The set of virulence factors present in a cell determines the site of infection, as
well as the ways of interaction with the host. Their presence and the level of their
expression promote the fitness and survival for a given strain when it encounters specific
environment. In certain species, i.e., E. coli, various pathotypes may exist, i.e., the
several groups of enteropathogenic types and ExPEC types (Köhler and Dobrindt, 2011;
Wilson et al., 2002; Wu et al., 2008). The most common virulence factors of ExPEC are
shown in Table 4. (Dale and Woodford, 2015).

Beyond these specific virulence factors directly involved in host-parasite
interactions, other cellular components may have an indirect, or still to be understood
direct role, in the pathogenesis or fitness of the isolates. One such component is the core
of the lipopolysaccharide molecule, a structure specifically studied in my project.
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Table 4: ExPEC virulence factors
Virulence Factors Gene (S)

Gene (S)

Adhesion siderophore
Dr binding adhesins
E. coli common pilus
F1C fimbriae
Heat-resistant haemagglutinin
M fimbriae
N-acetyl D-glucosamine-specific fimbriae
P fimbriae
S fimbriae
Temperature sensitive haemagglutinin
Type 1 fimbriae
Iron acquisition systems
Aerobactin receptor
Peri-plasmic iron binding protein
Salmochelin receptor
Siderophore receptor
Yersiniabactin receptor
Protectins and invasins
Colicin V
Conjugal transfer surface exclusion protein
Group 3 capsule
Increased serum survival
Invasion of brain endothelium
K1/K2/K5 group 2 capsule variants
kpsM II group 2 capsule
Outer membrane protease T
Toxins
α-haemolysin
Cytolethal distending toxin
Cytotoxic necrotising factor
Enteroaggregative E. coli toxin
Haemolysin A
Secreted autotransporter toxin
Serine protease
Vacuolating toxin
Others
ß-glucoronidase
Colibactin synthesis
Uropathogenic-specific protein
Flagellin variant
Maltose and glucose-specific PTS transporter subunit IICB
Pathogenicity island marker
D-serine deaminase

iha
afa/draBC
ecpA
foc gene cluster
hra
bmaE
gaf
papACEFG
sfa/sfaS
tsh
fimH

Adhesins

iutA
sitA
iroN
ireA
fyuA
cva
traT
kpsMT III
iss
ibeA
K1/K2/K5 genes
kpsM II
ompT
hlyD
cdtB
cnf1
astA
hlyA
sat
pic
vat
uidA
clb & clbB
usp
H7 fliC
malX
malX
DsdA
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1.7.1 The Core Region of Lipopolysaccharide

The lipopolysaccharide (LPS) of Gram-negative cell envelope forms the outer
leaflet of the outer membrane (Figure 3.) (Donnenberg, 2015; Murray et al., 2012).
Connecting the inner, highly conserved

Lipid A part, i.e., the endotoxin, to the

outermost, highly variable O-specific side chain of LPS is the core. It is made of
oligosaccharide components and commonly contains sugars such as heptose and 3deoxy-D-mannooctulosonic acid (also known as KDO, keto-deoxyoctulosonate) (Amor
et al., 2000; Wang and Quinn, 2010). The core oligosaccharide (OS) forms a linear or a
branched structure. The core-OS region can be divided into two regions: the inner and
outer cores (Figure 3.). The inner core is attached directly to lipid A and is less variable
and its composition is normally characteristic of a genus or family (Wang and Quinn,
2010).

The outer core region is more variable, being the part more exposed towards the
external pressures. It is normally referred to as the hexose region, and is usually
composed of neutral and basic hexoses (Frirdich and Whitfield, 2005; Wang and Quinn,
2010). By comprehensive study and sequence analysis for the chromosomal waa loci,
Amor et al. have developed a PCR-based LPS core typing system for E. coli isolates
(Amor et al., 2000).
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Figure 3: The envelope of Gram-negative bacteria
(Beutler and Rietschel, 2003).

In E. coli there are 5 core types distinguished: R1-4 and K-12 (Frirdich and
Whitfield, 2005). Importantly, studies in the 1990s and early 2000s found that the
distribution of these core types among commensal strains and those isolated from
clinical cases were uneven. Among E. coli isolated from human blood stream infection
(BSI) R1 (69.4%) was the most common followed by R2 (11.1%) , R3 (11.1%), K-12
(5.6%) and R4 (2.8%) respectively (Appelmelk et al., 1994; Gibb et al., 1992). These
frequencies were well reflected by the distribution of core-type-specific antibodies in the
population (Gibbs et al., 2004). However, it has been noticed lately that previously rare
core types R4 and K-12 have become more common, at least in animal infections (Duda
et al., 2011). More recently, it was found in our laboratory that strains isolated from
urinary tract infections in the United Arab Emirates exhibited a

surprisingly high

frequency of the K-12 core type (44.6%) among ESBL producing strains that was
clearly associated with the ST131 MDR clone (see later) (Szijártó et al., 2012). Based on
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these data, the possibility that newly emerging clones could have an advantage if
expressing previously rare core types was raised (Szijártó et al., 2012).

1.7.2 The Relationship Between Antimicrobial Resistance and Fitness/Virulence

Antimicrobial resistance and bacterial virulence have developed independently;
nevertheless, they share some common characteristics. Both are to counteract
mechanisms which, if successful, could eliminate the microbe (Beceiro et al., 2013;
Martínez and Baquero, 2002). In some cases, the association between fitness and
resistant antimicrobial actions are caused by being shielded in unique niches, i.e.,
intracellularly or within the matt of biofilms (Patel, 2005). Some microbial mechanisms,
e.g. efflux pumps, may affect both, resistance and fitness, as well, as they may eliminate
from the cells not only compounds that could potentially prevent colonization of the
host, but also antimicrobials (Opal and Pop-Vicas, 2015; Poole, 2002). However, the
connection is often inverse: an overexpression of an efflux pump or the down regulation
or loss of porins might be needed for survival in an antibiotic rich environment, but may
affect negatively the fitness of the cells (Doumith et al., 2009; Yang et al., 2010).

A further, unique, way of linking drug resistance and virulence together is the colocation of fitness/virulence and antibiotic resistance genes on the same, usually mobile,
genetic elements, such as plasmids. Not only that in this case the two features could
spread together horizontally, but also they are co-selected for, i.e., within the host the
pressure to be fit also would also mean selection for being resistant (Beceiro et al.,
2013).
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So, the possible links between fitness/virulence and antimicrobial resistance is
not unidirectional, i.e., not necessarily the most fit/virulent strains are the most resistant
ones and vice versa. What is clear is that certain resistant clones have a unique capacity
to spread. They are often mentioned as the ―International High Risk MDR Clones‖
(Mathers et al., 2015).

1.8 International High Risk MDR Clones
During the past decade, an increasingly trend has been observed, i.e., a
considerable part of the outbreaks by MDR Enterobacteriaceae being due to a limited
number of related strains, i.e., clones. In some cases, the clones were clearly
homogenous, while in others the level of heterogeneity regarding the features of the
clones, including virulence, as well as the mechanism and spectrum of their antibiotic
resistance varied (Mathers et al., 2015).

1.8.1 E. coli High Risk Clones

One of the best studied example of such clones is the E. coli ST131 (O25:H4)
clone which has recently been responsible for the increasing proportion of extraintestinal
infections caused by this species. Initially, the clone was associated with CTX-M type,
mostly, but not exclusively the CTX-M-15 type ESBLs (Pitout, 2010; Pitout, 2012)
significantly contributing to the global spread of this enzyme (Naas et al., 2008) (Figure
4.). Today, a substantial proportion of MDR ExPEC belong to ST131 and it is described
as a ST-lineage pandemic (Al-Agamy et al., 2014; Blanco et al., 2011; Bonnet, 2004).
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Figure 4: Global distribution of CTX-M genotypes
(Hawkey and Jones, 2009).
As a result, in many parts of the world 10–40% of E.coli and K. pneumoniae strains
express ESBLs (Rupp and Fey, 2003). Most importantly, members of the same clone
have been described to carry other type of ß-lactamases, such as carbapenemases
(Peirano et al., 2011). Beyond ST131, several STs of E. coli have been described as
international clones: e.g. ST10, ST12, ST38, ST73, ST95, ST127, ST393, ST405, and
ST648 (Petty et al., 2014; Riley, 2014; Wirth et al., 2006; Woodford et al., 2011).

The spread of E.coli lineages has been associated with certain resistance patterns.
For example, ST69 is globally recognized as resistant primarily to trimethoprimsulphamethoxazole, but not regularly as an ESBL-producing clone. Other, very common
ExPEC lineages, like ST73 and ST95, are common causes of UTI, but are rarely
multidrug resistant (Riley, 2014). The ST405 was recently described as an E. coli clone
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disseminating CTX-M-15 ESBL on a global scale (Coque et al., 2008; Hrabák et al.,
2009). The ST393 has also emerged as a MDR ExPEC. It is considered as member of
the ST131 complex where it is associated with CTX-M-type ESBLs without losing
virulence (Olesen et al., 2009). As mentioned earlier, the ST131 is associated closely
with ESBL-production and quinolone resistance (Olesen et al., 2013). However, while
most ST131 isolates belong to serotype O25, a sub-group has recently been identified as
O16 (Banerjee and Johnson, 2014; Zhong et al., 2015). O25b:H4 serotype strains are
commonly

resistant

to

fluoroquinolones,

aminoglycosides,

trimethoprim-

sulfamethoxazole and extended-spectrum cephalosporins (Banerjee et al., 2013; Dashti
et al., 2014).

1.8.2 K. pneumoniae High Risk Clones

Clonality is not restricted to E. coli. Most MDR K. pneumoniae isolates, which
produce ESBLs and carbapenemases, often in combination with quinolone and
aminoglycoside resistance, belong to particular clones. There are a number of STs of K.
pneumoniae strains associated with multidrug resistance: ST23, ST26, ST101, ST380,
ST86, ST57, ST65, ST375, ST11, ST14, ST15, ST258 and ST512 (Baraniak et al., 2013;
Bialek-Davenet et al., 2014; Breurec et al., 2013; Brisse et al., 2009; Woodford et al.,
2011). Isolates that express capsule serotype K1 and are associated with pyogenic liver
abscess belong to ST23 and ST57 and placed to Clonal Group (CG) 23 (Brisse et al.,
2009; Merlet et al., 2012; Turton et al., 2007). On the other hand, STs associated with
serotype K2 were distributed into 3 main CGs: CG86, CG375, and CG380. In fact, K2
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isolates associated with severe community-acquired infections are genetically more
diverse than K1 isolates (Bialek-Davenet et al., 2014).

Large outbreaks caused by successful clones of K. pneumoniae have been
reported since the early 1990s in several countries (Arena et al., 2013). Inn Hungary,
epidemic K. pneumoniae clones with CTX-M-15 were assigned to ST11, ST15 and
ST147 (Damjanova et al., 2008). In the USA, Klebsiella pneumoniae carbapenmase
(KPC) producing isolates belonging to ST258 were identified in 10 of the 19 states
reporting such strains (Kitchel et al., 2009). In addition, ST258 have been reported from
Brazil, China, Argentina, Colombia, Hungary, France, Greece, Poland, India, Israel,
Norway, Scotland, and Sweden (DeLeo et al., 2014; Munoz-Price et al.; Nordmann et
al., 2011)

1.8.3 The Virulence of High Risk E. coli Clones

Although the clonal dissemination of ExPEC and that of ESBL producing or
carbapenem resistant K. pneumoniae (CRKP) strains is globally recognized and
reported, the mechanism of their spread is not well understood. Usually, these strains are
associated with both community-onset and healthcare-associated infections, in particular
urinary tract and bloodstream infections (Hrabák et al., 2009; Riley, 2014).

E. coli ST131 (O25b:H4) exhibit a wide array of virulence factors (Johnson,
1991; Pitout et al., 2005). However, the relationship between virulence and drug
resistance is rather complex (Beceiro et al., 2013). A study found that resistance to
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quinolones, i.e., a common feature within this clone, is linked to a loss of virulence
factors. At the same, time the low virulent phylogenetic groups might be more prone to
acquire resistance to quinolones (Chakraborty et al., 2015; Da Silva and Mendonça,
2012). Another study found that the rate of virulence factors among pathogenic E. coli
strains isolated from human blood and urine was higher in the phylogenetic group B2.
Alpha-hemolysin, yersiniabactin receptor (fyuA), serum resistance-associated outer
membrane protein (traT) and aerobactin receptor (iutA) were found to be independent
predictors for pathogenicity. Of these virulence factors, iutA and traT were significantly
more common in strains producing the blaCTX-M-1 group and the blaCTX-M-9 group ESBLs,
respectively (Lee et al., 2010). In contrast, another report found that the production of a
CTX-M-1 enzyme does not appear to affect virulence (Dubois et al., 2009).
Furthermore, the B2 epidemic strains circulating in the United Kingdom expressing
CTX-M-15 did not appear to be more virulent, despite iutA and fyuA being more
prevalent in these than in non-clonal CTX-M-15 producing isolates (Branger et al.,
2005; Lee et al., 2010). In fact, it seems that there are significant differences in the
prevalence of individual virulence factors among CTX-M producers and non-producers
(Karisik et al., 2008; Pitout et al., 2005).

Certain ExPEC STs associate simultaneously with both high level of resistance
and virulence, enabling them to cause major outbreaks at different locations (Table 5.)
(Riley, 2014). This combination certainly provides a competitive advantage and ability
for the clonal dissemination worldwide (Naseer and Sundsfjord, 2011; Van der Bij et al.,
2012). The dissemination of the resistant strains takes place either by medical tourism or
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other human activities, or by contaminated vehicles or food products (Adams-Sapper et
al., 2012; Dale and Woodford, 2015; Riley, 2014)

Table 5: Phenotypic and genotypic characteristics of pandemic ExPEC E. coli clonal
lineages
MLST

ST393

Serogroups,
serotypes

O15b:K52:H1

phylogenetic
group

D

ST131

O25b:H4, O16:H5,
NT:H4, O157

B2

ST69

O11, O15, O17,
O44, O73,
O77, O86, O125ab,
O25b

D

ST95

O1:K1:H7,
O2:K1:H7,
O18:K1:H7,
O45:K1:H7

B2

ST73

O6:H

B2

Prototypic virulence factor genes
iha (adhesin-siderophore), fimH (type 1
fimbriae), fyuA (yersiniabactin
receptor),
iutA (aerobactin receptor), and kpsM II
(group 2 capsule)
iha and fimH (adhesins), sat (toxin),
fyuA/irp2 and iutA/iucD (siderophore
systems),
kpsM II, usp (uropathogenic specific
protein), traT (serum resistanceassociated),
ompT (outer membrane protease), and
malX (pathogenicity island marker)
F10 and F16 papA alleles, papG allele
II, sfa/focDE (S and F1C fimbriae),
focG
(F1C fimbriae adhesin), iha, hlyD, cnf1,
fyuA, iutA, iroN, malX, and afa/dra
(Dr antigen-binding adhesins), cdtB,
and K1 kpsMT
fimH, fimAvMT78, papG II, iucD, iroN,
kpsM II-K1, cvaC, iss, traT, malX, usp,
and tsh
papC, papEF, papG, sfa/foc, fimH, hra,
hlyA, cnf1, pic, vat, iroN, fyuA, kpsM II,
usp, and ompT
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1.8.4 The Virulence of High Risk K. pneumoniae Clones

The virulence-related genes of globally distributed clonal groups of K.
pneumoniae has also been investigated in several studies. The type-3 fimbriae cluster
mrkABCDF was almost universally present, and plasmid-associated clusters
pcoABCDERS (copper-resistance) and silCERS (silver-resistance) were widely
distributed. In contrast, some other genes were mainly associated with particular Clonal
Groups (CGs). The allantoinase cluster was present only in members of CG23 and ST25.
Some or all isolates of the major CGs associated with community-acquired invasive
infections (CG23, CG86, CG375, and CG380) harbored the 2 well-recognized virulence
factors, iucABCDiutA (aerobactin synthesis) and rmpA (the positive regulator of mucoid
phenotype), in addition to the yersiniabactin siderophore cluster and, except for CG23,
the 2-component regulatory system kvgAS. These results reinforce the view that CG23,
CG86, CG375, and CG380 represent hypervirulent CGs of K. pneumoniae (BialekDavenet et al., 2014; Bialek-Davenet et al., 2013). Several other STs and CGs (ST25,
CG65, ST66, ST90 and ST382) also harbored virulence genes, suggesting additional
hypervirulent clones, which is also supported by the clinical origin of some isolates of
these STs. In contrast, CG258 was almost entirely devoid of virulence genes (BialekDavenet et al., 2014; Bialek-Davenet et al., 2013; Bogaerts et al., 2010; Woodford et al.,
2011)

On the other hand, a study found that the ability of ESBL producing and nonproducing K. pneumoniae strains to express type 1 and 3 fimbrial adhesins were not
different significantly (Sahly et al., 2008). Conversely, the ability of ESBL producers

38

strains to invade ileocecal and bladder epithelial cells was significantly higher (81% and
27.6%, respectively) than non-ESBL producers (61% and 10%, respectively), possibly
due to the capacity to up regulate the expression of one or more invasion related genes.
Nevertheless, it is still unclear whether this effect resulted from the direct expression of
the blaSHV-type ESBL gene or from the expression of another plasmid-borne gene(s)
(Beceiro et al., 2013; Sahly et al., 2008).

As seen from the existing controversies, contrary to the abundance of data, still,
very little is understood on the association between virulence and resistance, resistance
and the ability to spread, and resistance to antibiotics and disinfectants. This study aimed
to shed some lights on these questions, from the local, i.e., Arabian Gulf, perspective.
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Chapter 2: Aims and Objectives
2.1 Long Term Aims
The long term aim of the project is to contribute to a better understanding of the
epidemiology of multidrug resistant Klebsiella pneumoniae and Escherichia coli in the
Arabian Peninsula by understanding the dominant clones and the features in which
clonal isolates differ from their sporadic counterparts.

2.2 Specific Objectives
A. To characterize blood-stream E. coli isolates by:
-

genotyping by PCR targeting virulence and antibiotic resistance genes

-

assessing their antibiotic resistance

-

establishing the clonal structure of the collection by macrorestriction analysis
and multilocus sequence typing

B. To characterize the virulence, antibiotic susceptibility and clonal structure of
carbapenem resistant K. pneumoniae collected in the Arabian Peninsula by:
-

genotyping by PCR targeting virulence and antibiotic resistance genes

-

assessing their antibiotic resistance

-

subjecting the strains to macrorestriction analysis and multilocus sequence typing

-

assessing their serum sensitivity and biofilm forming capacity
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C. To compare the biocide susceptibility of carbapenem resistant and susceptible E.
coli and K. pneumoniae isolates by:
-

determining the quantitate susceptibility to chlorhexidine, benzalkonium and
irgasan

-

testing for the presence of a panel of chromosomally coded, as well as plasmid
located genes associated with disinfectant resistance

D. To compare the susceptibility of carbapenem resistant and susceptible K
pneumoniae strains to fosfomycin, i.e., an antibiotic currently not available in the
UAE for parenteral use by:
-

determining the quantitative susceptibility of the isolates to fosfomycin and
comparing it to susceptibilities to tigecycline and colistin, i.e., the other ―last
resort‖ drugs

-

investigating the genetic background of fosfomycin resistant strains encountered
by PCR-genotyping
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Chapter 3: Material and Methods
3.1 Bacterial Strains

A total of 337 strains including 172 E. coli and 165 K. pneumoniae were
included in various parts of the study. The specific numbers used for each project and
their actual selection criteria and sources are detailed when describing the actual results.
Duplicate isolates from the same patients were excluded and only the first isolate from
each case was included. The strains were speciated by the laboratories of the
participating hospitals using standard microbiological procedures (e.g. API or VITEK 2
identification panels). When strains with a specific resistance type were collected (e.g.
strains non-susceptible to carbapenems), this was done based on the results of tests run
in the submitting laboratories. However, the resistance patterns were always confirmed
by us (see later). All isolates were stored in duplicates in Tryptic Soy Broth (TSB),
(MAST, UK) containing 10% glycerol (Univar, USA) in two separate -80oC freezers
being on independent electrical circuits. Prior to each experiment, strains were revived
onto Tryptic Soy Agar (TSA), (MAST, UK) by incubating for 24 h at 37 C.

3.2 Antibiotic Susceptibility Testing

All tests were carried out and evaluated by the Clinical Laboratory Standard
Institute (CLSI) standards (CLSI, 2014), except for tigecycline, for which no breakpoint
values are currently available in this system. In this case we used the ones recommended
by EUCAST (www.eucast.org/clinical-breakpoints).
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Qualitative antibiotic susceptibility testing was conducted by the Kirby-Bauer
(disc diffusion) method. Fresh cultures grown on TSA plates were suspended in sterile
1xPBS to 0.5 McFarland density and applied onto ready-made Mueller-Hinton agar
(MHA) plates (Pangulf Lab Solution, UAE) with a swab (Citoswab, China) to provide
semi-confluent growth. Antibiotic disks (MAST, UK) were applied using an applicator,
seven discs per/ 90 mm dish. Plates were incubated for 18 h at 37oC. The diameters of
the zone of inhibition were measured with a caliper. Susceptibilities were established
against amikacin (AK), ampicillin (AP), augmentin (AUG), aztreonam

(AZT),

ceftazidime (CAZ), chloramphenicol (CHL), ciprofloxacin (CIP), colistin (COL),
cefpodoxim (CPD), cefotaxime (CTX), cefuroxime (CXM), doxycycline (DXT),
ertapenem (ERT), fosfomycin (FOS), cefoxitin (FOX), gentamicin (GN), imipenem
(IMP), meropenem (MEM), netilmicin

(NET), piperacillin-tazobactam (PTZ),

trimethoprim-sulphamethoxazole (SXT), tigecycline (TGC), ticarcillin/clavulanic acid
(TIM) and tobramycin (TOB).

For quantitative assay the broth microdilution assay was used. Antibiotics were
serially diluted in 100 µl volume of Muller Hinton Broth (MHB), (MAST, UK) in 96
well microplates (Nunc, USA) and inoculated by a Multipoint inoculator (MAST, UK)
to give a final concentration of 5 x 105 colony forming units (CFU)/ml. After 18 hours of
incubation at 37 oC, the growth was visually assessed and the Minimum Inhibitory
Concentration of the drug (MIC) was determined as the lowest concentration preventing
visible growth of the organism tested. The quantitative susceptibility test was established
against: imipenem (IMP), meropenem (MEM), ertapenem (ERT), ceftazidime (CAZ)
and cefotaxime (CTX) respectively. For fosfomycin (FOS), tigecycline (TGC), colistin
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(COL), the agar dilution method was used to determine the MIC. Different
concentrations of antibiotics were prepared in 1 ml and added to 24 ml of MHA plate
(MAST, UK). A 1:10 dilution of bacteria was prepared by adding 100 µl of 0.5
McFarland to 900 µl of 1XPBS, to give a final concentration of 104/µl. One µl of this
suspension was delivered by the multipoint inoculator, i.e., approximately 104 CFU/dot
was inoculated.

For all sensitivity assays, Escherichia coli ATCC 25922 strain was used as a
susceptible control.

3.3 Detection of MIC of Disinfectants

Pure substances of triclosan (Irgasan) (IRG) (5-chloro-2-(2,4-dichlorophenoxy)
phenol), chlorhexidine (CHEX) (1,1′-Hexamethylenebis[5-(4-chlorophenyl) biguanide],
and benzalkonium chloride (BENZ) (Alkylbenzyldimethylammonium chloride) were
purchased from (SIGMA, USA). The MIC of disinfectants was determined by agar
dilution assay. Different concentrations of biocides were prepared in 1 ml and added to
24 ml of MHA plate (MAST, UK). 1:10 dilution of the bacteria was prepared by adding
100 µl of 0.5 McFarland to 900 µl of 1XPBS to give a final concentration of 104/µl.

3.4 Detection of ESBL Production

This test was performed based on the CLSI criteria (CLSI, 2014) using MHA
plates (Oxoid, Basingstoke, UK). The double disc synergy test was used to confirm
ESBL production using a disc containing amoxicillin/clavulanic acid placed in the center
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of the inoculated plate and discs containing various cephalosporins and aztroneam
placed around 20 mm apart from the central disc. The strains exhibiting the ―keyhole‖
were considered as an ESBL producer (Apfalter et al., 2007; Bell et al., 1999).

3.5 Detection of Carbapenemase Production (Modified Hodge Test)

The general presence of carbapenemases were assessed by the modified Hodge
Test (CLSI, 2014). MHA plates (Pangulf Lab Solution, UAE) were inoculated with a 0.5
McFarland suspension of E.coli ATCC 25922. Ertapenem susceptibility disks were
placed on the center of the plate. The test strain, a carbapenemase non-producing
negative control strain (E. coli K-12 J53), and a KPC producing positive control (GRKPC2) were streak-inoculated towards the disc. The plate was incubated overnight at
37oC. After 16-24 hours, the plate was examined for a cloverleaf-type indentation at the
intersection of the test organism and E.coli 25922.

3.6 Carba NP Test

Carba NP test was performed as described (Nordmann et al., 2012b). One
calibrated loop (10 μL) of the test strain was suspended in a Tris-HCl 20 mmol/L lysis
buffer (B-PERII, Bacterial Protein Extraction Reagent; Thermo Scientific Pierce,
Rockford, IL, USA), vortexed for 1 minute and further incubated at room temperature
for 30 minutes. This bacterial suspension was centrifuged at 10,000 × g at room
temperature for 5 minutes. Thirty μL of the supernatant, corresponding to the enzymecontaining extract, was mixed in a 96-well plate with 100 μL of a 0.3% of Imipenem
monohydrate solution (Sigma, Saint-Quentin Fallavier, France). Plates were incubated at
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room temperature for a maximum of 2 hours. For carbapenemase producers, the color of
the wells turned from red to orange or yellow. On the other hand, the color of the wells
remained red if no carbapenemase activity was present.

3.7 Detection of Biofilm Production by Klebsiella pneumoniae
Klebsiella pneumoniae were sub-cultured on TSA plates and incubated at 37 oC.
Next day 2 ml of Luria Broth (LB), (Invitrogen, USA) was inoculated and incubated
with this bacterial strain overnight at 37 oC. On the third day, 2 ml aliquots of 1X M63
broth supplemented with 20% Casamino Acid (CA), (BD, USA) and 0.2% glucose were
inoculated with 10 μl of the bacterial suspension. Hundred μl aliquots of these
suspensions were distributed into 96-wells plate (Nunc, USA), 4 wells per strain, and
incubated overnight at 37 oC for 18 hours. Un-inoculated wells containing medium only
served as negative controls. On the day four, 25 μl of 1% crystal violet were added to all
wells. The plates were incubated at room temperature for 15 minutes. After the
incubation period, the content of the wells was aspirated and washed 3X with 200 μl
with distilled water. After that, the 96-wells plates were air dried at room temperature
overnight. Next, 200 μl of lysing solution (1% SDS, 50% Ethanol, 1% PBS) were added
and plates were gently shaken on a tilting table for 30 minutes. The optical density of the
dissolved, dye-binding masses of biofilm forming bacteria was measured at 570 nm.

The results were evaluated using an arbitrary scheme (Novais et al., 2012)
defining the cut-off optical density value (ODc) for biofilm production as the mean +
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three standard deviations of OD of the sterility control. The strength of biofilm
production was scored as seen on Table 6.

Table 6: Scoring system for the extent of biofilm production
Score
Nonadherent
Weakly
Moderately
Strongly

OD
≤ODc
ODc < OD ≤ 2 ODc
2 ODc < OD ≤ 4 ODc
> 4 ODc
ODc – Cut-off optical density

3.8 Detection of Serum Resistance

Serum resistance were assayed by method of King et al. (King et al., 2009).
Briefly, fresh cultures grown on TSA plates at 37°C were suspended in sterile 0.9%
NaCl to 0.5 McFarland density. Normal human serum (NHS) was prepared from the
blood of 4 healthy individuals. After clotting at room temperature, serum was separated
by centrifugation for 30 minutes at 3,500 rpm at 37C. Sera was pooled and stored in
aliquots at -80°C until use.

0.5 McFarland bacterial suspensions were diluted 50 times to get 2x106 CFU/ml
by adding 40 μl of 0.5 McFarland suspension to 1960 μl 0.9% saline. 25 μl of 50 X
bacterial suspension were mixed with 75 μl pre-warmed (37 oC) NHS in a microtitre
plate (Nunc, USA), in parallels . Immediately after mixing, 20 μl of the first parallel was
taken for 10X serial dilutions (-1, -2, -3) to determine the original germ count (zero
time). The plate then was incubated at 37 °C for 3 hours. Again, a 20 μl of the 3 parallels
were taken for serial dilutions (-1, -2, and -3) to determine the germ count after 3 hours
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of incubation. Viable counts were determined after 18 hours of incubation by plating 25
μl of each serial dilution on TSA plate for colony counts. In every experiment, a serum
sensitive (K. pneumoniae 1321) and a highly resistant strain (K. pneumoniae 1023) were
included. Serum sensitivity of strains was evaluated according to Sharma et al., 1999.
Strains were considered susceptible if the initial count was reduced to <1% of the 0 time
CFU, while if >90% survived, the strain was considered resistant. Strains between these
two values were considered intermediate.

3.9 Extraction of Bacterial Genomic DNA for PCR

Three to five colonies of strains grown overnight on TSA plates were picked by
toothpick and suspended into two 200 μl aliquots of sterile distilled water in Eppendorf
tubes. The tubes were incubated for 10 minutes at 99˚C in a thermo-block (Eppendorf)
and centrifuged for 10 minutes at 14,800 rpm. Supernatant of both tubes was collected
without touching the pellet, combined in a new autoclaved Eppendorf tube and kept at
4˚C. This material was used for most experiments as the DNA target. Whenever doubts
were raised on the quality of DNA material (e.g. fuzzy amplicons, unexpected results),
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Germany) according to
the manufacturers‘ instruction.

3.10 Genotyping by PCR

Before subjecting DNA samples for further testing, a PCR reaction targeting the 16S
ribosomal RNA gene was carried out to establish the presence of bacterial DNA (Louie
et al., 2002). The entire gene was amplified using flanking forward primer 5‘-
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GACGTACTCGCAGAATAAGC-3‘

and

reverse

primers,

5‘-

TTAGTCTTGCGACCGTACTC-3‘.

PCR reactions were performed on Applied Biosystems 2700 and 2720
thermocyclers. In all reactions, E. coli J53RAZ genomic DNA and ultra-pure distilled
water were used as negative controls. All positive reactions first obtained were
confirmed by direct sequencing. The genes targeted and the primers and parameters used
in different PCR reactions with respective references are listed in Table 7. Amplified
DNA was loaded on 1-2% agarose gels (Promega, US) in the presence of ethidium
bromide dye (Sigma, USA), and the gels were examined and photographed at 302 nm
using the Biometra Gel Documentation System (Biometra, Göttingen, Germany). To
assess the molecular mass of the amplicons, Gene Ruler 100 bp DNA ladder
(Fermentas) standards were run on each gel.

3.11 Conjugation

For conjugation experiments, J53RAZ (a Na-azide resistant in-house derivative of
the rifampin resistant J53 E. coli K-12) was used as the recipients. Four hour TSB
cultures of the donor and recipient were combined in a 1:4 ratio and were incubated for
4 hours at 37oC without shaking. The mixture was centrifuged at 3500 rpm for 15
minutes and the pellet was re-suspended in 200 μl of TSB. 100 μl of the suspension was
dropped onto a TSA plate to continue conjugation, this time on a solid surface. Next
day, the growth was collected in PBS. Serial dilutions were plated onto plates containing
150 μg/ml azide plus the antibiotic selection marker. In our case, this was 4μg/ml
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fosfomycin and 25 μg/ml glucose-6 phosphate. Next day, colonies were collected and
subjected to plasmid electrophoresis to ensure that transconjugants and not mutants of
the donor or recipient were obtained.
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Final
extension

Cycle

Initial
Denaturation

PCR product
size

Sequences
(5’- 3’)

Primers

Gene
targeted

Table 7: Primers and PCR protocols used in this study

Detection of ESBL genes singleplex PCR to detect TEM, SHV, CTX-M & GES

blaTEM

C
D

TCG GGG AAA TGT GCG CG
TGC TTA ATC AGT GAG GCA CC

971bp

5‘at
94˚C

blaSHV

OS-5
OS-6

TTA TCT CCC TGT TAG CCA CC
GAT TTG CTG ATT TCG CTC GG

798bp

5‘ at
94˚C

blaPER

PER-A
PER-B

ATG AAT GTC ATT ATA AAA GC
AAT TTG GGC TTA GGG CAG AA

925bp

5‘at
94˚C

blaCTX-M

MA-1
MA-2

SCS ATG TGC AGY ACC AGT AA
CCG CRA TAT GRT TGG TGG TG

543bp

5‘ at
94˚C

774bp

5‘ at
94˚C

blaGES

GES-1A
GES-1B

ATG CGC TTC ATT CAC GCA C
CTA TTT GTC CGT GCT CAG G

30 X (30‖ at
94˚C- 30‖ at
60˚C and
60‖ at 72˚C)
30X(45‖ at
94˚C, 55‖ at
60˚C and
60‖ at 72˚C)
35X (45s at
94˚C, 60‖ at
52˚C and
60‖ at 72˚C)
30X (30‖ at
94˚C, 30‖ at
55˚C and
60‖ at 72˚C)
35X (45‖ at
94˚C, 60‖ at
52˚C and
60‖ at 72˚C)

10‘ at
72˚C
5‘at
72˚C
10‘at
72˚C

(Cao et al.,
2002)

10‘ at
72˚C
7‘ at
72˚C

Detection of AmpC gene multiplex PCR
MOX-1,
MOX-2,
CMY-1,
CMY-8 to
CMY-11
LAT-1 to
LAT-4,
CMY-2 to
CMY-7,
BIL-1

MOXMF
MOXMR

CITMF
CITMR

GCT GCT CAA GGA GCA CAG GAT
CAC ATT GAC ATA GGT GTG GTG C

TGG CCA GAA CTG ACA GGC AAA
TTT CTC CTG AAC GTG GCT GGC

520
bp
5‘ at
94˚C
462
bp

30 X (30‖ at
94˚C, 30‖ at
64˚C and
60‖ at 72˚C)

10‘ at
72˚C

(PérezPérez and
Hanson,
2002)
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51
DHA-1,
DHA-2
ACC
MIR-1,
ACT-1
FOX-1 to
FOX-5b

DHAMF
DHAMR
ACCMF
ACCMR
EBCMF
EBCMR
FOXMF
FOXMR

AAC TTT CAC AGG TGT GCT GGG T
CCG TAC GCA TAC TGG CTT TGC

405bp

AAC AGC CTC AGC AGC CGG TTA
TTC GCC GCA ATC ATC CCT AGC

346bp

TCG GTA AAG CCG ATG TTG CGG
CTT CCA CTG CGG CTG CCA GTT

302bp

AAC ATG GGG TAT CAG GGA GAT G
CAA AGC GCG TAA CCG GAT TGG

190bp

5‘ at
94˚C

30 X (30‖ at
94˚C, 30‖ at
64˚C and
60‖ at 72˚C)

10‘ at
72˚C

(PérezPérez and
Hanson,
2002)

40X (30‖at
94˚C, 40‖ at
52˚C, 50‖ at
72˚C)

10‘at
72˚C

(Poirel et
al., 2011b)

30X (30‖at
94˚C, 30‖ at
60˚C, 60‖ at
72˚C)

7‘ at
72˚C.

(Ghazawi et
al., 2012)

35 X (1‘ at
94˚C, 1‘ at
54˚C and 1‘
at 72˚C)

10‘ at
72˚C

(Cattoir et
al., 2007;
Fritsche et
al., 2008)

Detection of carbapenemase genes

blaOXA-48-like

OXA-F
OXA-R

GCGTGGTTAAGGATGAACAC
CATCAAGTTCAACCCAACCG

438bp

blaKPC

KPC-F
KPC-R

CGTCTAGTTCTGCTGTCTTG
CTTGTCATCCTTGTTAGGCG

798bp

blaVIM

VIM-F
VIM-R

GATGGTGTTTGGTCGCATA
CGAATGCGCAGCACCAG

390bp

blaIMP

IMP-F
IMP-R

GGAATAGAGTGGCTTAAYTCTC
GGTTTAAYAAAACAACCACC

232bp

NDM1-Fo
NDM1-Re

TGCCGAGCGACTTGGCCTTG
ACCGATGACCAGACCGCCCA

blaNDM-1

379bp

5‘ at
94˚C

5‘ at
94˚C

Detection of plasmid mediated quinolone resistance genes

qnrA

qnrB

QnrAm-F
QnrAm-R
QnrBm-F
QnrBm-R

AGAGGATTTCTCACGCCAGG
TGCCAGGCACAGATCTTGAC
GGMATHGAAATTCGCCACTG
TTTGCYGYYCGCCAGTCGAA

580
bp
264
bp

10‘
at
94˚C
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qnrS

QnrSm-F
QnrSm-R

GCAAGTTCATTGAACAGGGT
TCTAAACCGTCGAGTTCGGCG

428
bp

qepA

QepA-F
QepA-R

CTGCAGGTACTGCGTCATG
CGTGTTGCTGGAGTTCTTC

403
bp

AAC6′-Ib-cr1
AAC6′-Ib-cr2

TTGCAATGCTGAATGGAGAG
CGTTTGGATCTTGGTGACCT

218
bp

aac-6’-Ibcr

10‘
at
94˚C

35 X (1‘ at
94˚C, 1‘ at
54˚C and 1‘
at 72˚C)

10‘ at
72˚C

(Cattoir et
al., 2007;
Fritsche et
al., 2008)

5‘ at
94
˚C

40 X (15‖ at
94˚C, 30‖ at
58˚C, and 1‘
at 72˚C)

10‘ at
72˚C

(Fritsche et
al., 2008)

5‘ at
94˚C

35X (30‖ at
94˚C, 30‖ at
55˚C and
30‖ at 72˚C)

7‘at
72˚C

(Clermont
et al., 2000)

Detection of aminoglycoside 16S methyltransferase genes
armA

rmtA

rmtB

rmtC

armA-f
armA-r

TATGGGGGTCTTACTATTCTGCCTAT
TCTTCCATTCCCTTCTCCTTT

rmtA-f
rmtA-r

CTAGCGTCCATCCTTTCCTC
TTTGCTTCCATGCCCTTGCC

rmtB-f
rmtB-r

TCAACGATGCCCTCACCTC
GCAGGGCAAAGGTAAAATCC

rmtC-f
rmtC-r

GCCAAAGTACTCACAAGTGG
CTCAGATCTGACCCAACAAG

rmtD-f
rmtD-r

CTGTTTGAAGCCAGCGGAACGC
GCGCCTCCATCCATTCGGAATAG

Chu

ChuA.1
ChuA.2

GACGAACCAACGGTCAGGAT
TGCCGCCAGTACCAAAGACA

YjaA

Yja.A.1
Yja.A.2

TGAAGTGTCAGGAGACGCTG
ATGGAGAATGCGTTCCTCAAC

TspE4C2

TspE4C2.1
TspE4C2.2

GAGTAATGTCGGGGCATTCA
CGCGCCAACAAAGTATTACG

rmtD

514
bp
635
bp
459
bp

752
bp

376
bp
Detection of E. coli phylogenetic typing
279
bp

211
bp
152
bp

52

53
Detection of E. coli LPS core typing

R1
R2
R3
R4
K12

R1C3
R1K15

GGGATGCGAACAGAATTAGT
TTCCTGGCAAGAGAGATAAG

551
bp

R2C4
R2K9
R3C2
R3K13
R4C4
R4K14
K12-1
K12-2a

GATCGACGCCGGAATTTTTT
AGCTCCATCATCAAGTGAGA
GGCCAAAACACTATCTCTCA
GTGCCTAGTTTATACTTGAA
TGCCATACTTTATTCATCA
TGGAATGATGTGGCGTTTAT
TTCGCCATTTCGTGCTACTT
TAATGATAATTGGAATGCTGC

699
bp
1141
bp
1785
bp

1‘ at
94˚C

35X (20‖ at
94˚C, 30‖ at
50˚C and
135‖ at
72˚C)

5‘at
72˚C

(Amor et
al., 2000)

5‘ at
94˚C

35X (30‖ at
94˚C, 30‖ at
60˚C and
45‖ at 72˚C)

7‘at
72˚C

(Clermont
et al., 2008)

5‘ at
94˚C

35X (30‖ at
94˚C, 30‖ at
59˚C and
60‖ at 72˚C)

7‘at
72˚C

(Clermont
et al., 2007)

5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
56˚C and
60‖ at 72˚C)

10‘at
72˚C

(Wirth et
al., 2006)

916
bp

Detection of E. coli rfbO25b

rfbO25b

rfb.1bis
rfbO25.r

ATA CCG ACG ACG CCG ATC TG
TGC TAT TCA TTA TGC GCA GC

300
bp

Detection of E. coli rfbO16

rfbO16

adk

gndbis.f
rfbO16.r

adk F
adk R

ATACCGACGACGCCGATCTG
GGATCATTTATGCTGGTACG

E.coli MLST
ATTCTGCTTGGCGCTCCGGG
CCGTCAACTTTCGCGTATTT

450
bp

fumC F
fumC R

TCACAGGTCGCCAGCGCTTC
GTACGCAGCGAAAAAGATTC

583
bp
806
bp

gyrB

gyrB F
gyrB R

TCGGCGACACGGATGACGGC
ATCAGGCCTTCACGCGCATC

911
bp

icd

icd F
icd R

ATGGAAAGTAAAGTAGTTGTTCCGGCACA
GGACGCAGCAGGATCTGTT

878
bp

fumC

53

54
mdh

mdh F
mdh R

ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG
TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT

932
bp

purA

purA F
purA R

CGCGCTGATGAAAGAGATGA
CATACGGTAAGCCACGCAGA

816
bp

recA

recA F
recA R

CGCATTCGCTTTACCCTGACC
TCGTCGAAATCTACGGACCGGA

780
bp

5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
56˚C and
60‖ at 72˚C)

5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
50˚C and
60‖ at 72˚C)

5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
60˚C and
60‖ at 72˚C)

10‘at
72˚C

(Wirth et
al., 2006)

Klebsiella pneumoniae MLST
VIC3
VIC2

GGC GAA ATG GCW GAG AAC CA
GAG TCT TCG AAG TTG TAA CC

gapA

gapA173
gapA181

TGA AAT ATG ACT CCA CTC ACG G
CTT CAG AAG CGG CTT TGA TGG CTT

450
bp

mdh

mdh130
mdh867

CCC AAC TCG CTT CAG GTT CAG
CCG TTT TTC CCC AGC AGC AG

477
bp

pgi1F
pgi1R

GAG AAA AAC CTG CCT GTA CTG CTG GC
CGC GCC ACG CTT TAT AGC GGT TAA T

phoE604.1
phoE604.2

ACC TAC CGC AAC ACC GAC TTC TTC GG
TGA TCA GAA CTG GTA GGT GAT

infB1F
infB1R

CTC GCT GCT GGA CTA TAT TCG
CGC TTT CAG CTC AAG AAC TTC

tonB1F
tonB2R

CTT TAT ACC TCG GTA CAT CAG GTT
ATT CGC CGG CTG RGC RGA GAG

rpoB

pgi
phoE
infB

tonB

501
bp

432
bp

10‘at
72˚C
10‘at
72˚C

(Diancourt
et al., 2005)
5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
50˚C and
60‖ at 72˚C)

10‘at
72˚C

5‘ at
94˚C

35X (60‖ at
94˚C, 60‖ at
45˚C and
60‖ at 72˚C)

10‘at
72˚C

420
bp
318
bp
414
bp

54

55
Detection of E. coli virulence factors
hly

hly f
hly r
PapC f
PapC r

AACAAGGATAAGCACTGTTCTGGCT
ACCATATAAGCGGTCATTCCCGTCA
GTGGCAGTATGAGTAATGACCGTTA
ATATCCTTTCTGCAGGGATGCAATA

1177
bp
220
bp

PapA f
PapA r

ATGGCAGTGGTGTCTTTTGGTG
CGTCCCACCATACGTGCTCTTC

720
bp

PapEF f
PapEF r
FimH f
FimH r
RPAi f
RPAi r
FyuA f
FyuA r
bmaE-f
bmaE-r
sfa1
sfa2

GCAACAGCAACGCTGGTTGCATCAT
AGAGAGAGCCACTCTTATACGGACA
TGCAGAACGGATAAGCCGTGG
GCAGTCACCTGCCCTCCGGTA
GGACATCCTGTTACAGCGCGCA
TCGCCACCAATCACAGCCGAAC
TGATTAACCCCGCGACGGGAA
CGCAGTAGGCACGATGTTGTA
ATGGCGCTAACTTGCCATGCTG
AGGGGGACATATAGCCCCCTTC
CTCCGGAGAACTGGGTGCATCTTAC
CGGAGGAGTAATTACAAACCTGGCA

336
bp
508
bp
930
bp
880
bp
507
bp
410
bp

iutA

AerJ f
AerJ r

GGCTGGACATCATGGGAACTGG
CGTCGGGAACGGGTAGAATCG

300
bp

gafD

gafD-f
gafD-r
ColV-Cf
ColV-Cr
FocG f
FocG r
TraT f
TraT r
Afa f
Afa r
cnf1
cnf2
SfaS f
SfaS r
K5-f
kpsIIr

TGTTGGACCGTCTCAGGGCTC
CTCCCGGAACTCGCTGTTACT
CACACACAAACGGGAGCTGTT
CTTCCCGCAGCATAGTTCCAT
CAGCACAGGCAGTGGATACGA
GAATGTCGCCTGCCCATTGCT
GGTGTGGTGCGATGAGCACAG
CACGGTTCAGCCATCCCTGAG
GGCAGAGGGCCGGCAACAGGC
CCCGTAACGCGCCAGCATCTC
AAGATGGAGTTTCCTATGCAGGAG
CATTCAGAGTCCTGCCCTCATTATT
GTGGATACGACGATTACTGTG
CCGCCAGCATTCCCTGTATTC
CAGTATCAGCAATCGTTCTGTA
CATCCAGACGATAAGCATGAGCA

952
bp
680
bp
360
bp
290
bp
559
bp
498
bp
240
bp
159
bp

papC

papAH
papEF
fimH
PAI
fyuA
bmaE
sfa/focDE

cvaC
focG
traT
afa/draBC
Cnf1
sfaS
K5

5‘at
94˚C

25X (30‖ at
94˚C, 30‖ at
63˚C and
120‖ at
72˚C)

10‘at
72˚C

(Johnson
and Stell,
2000)
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rfc
nfaE

KpsMT II
KpsMT III
ibeA
K1
iha
Saa
toxB
UpaH
UpaB
Sat
ireA
ironN
Usp

cdt B

rfc-f
rfc-r
nfaE-f
nfaE-r
kpsII f
kpsII r
kpsIII f
kpsIII r
ibe10 f
ibe10 r
K1-f
kpsIIr
iha-I
iha-II
SAADF
SAADR
toxB911F
toxB1468 R
upaH f 524
upaH r 525
CO426.s-5
CO426.s-3
sat-f
sat-r
ireA-f
ireA-r
ireN-f
ireN-r
usp-f
usp-r

ATCCATCAGGAGGGGACTGGA
AACCATACCAACCAATGCGAG
GCTTACTGATTCTGGGATGGA
GCTTACTGATTCTGGGATGGA
GCGCATTTGCTGATACTGTTG
GCTTACTGATTCTGGGATGGA
TCCTCTTGCTACTATTCCCCCT
AGGCGTATCCATCCCTCCTAAC
AGGCAGGTGTGCGCCGCGTAC
TGGTGCTCCGGCAAACCATGC
TAGCAAACGTTCTATTGGTGC
CATCCAGACGATAAGCATGAGCA
CAG TTC AGT TTC GCA TTC ACC
GTA TGG CTC TGA TGC GAT G
CGT GAT GAA CAG GCT ATT GC
ATG GAC ATG CCT GTG GCA AC
ATA CCT ACC TGC TCT GGA TTG A
TTC TTA CCT GAT CTG ATG CAG C
AGT GAA GGG GCA AAA ACC TT
TGA AAC CAC CAC CAT TCT GA
GGA AAG GCA AAG TTT CAG GG
GGT GGT ATG TTT CTG TTT AC
ATG CCG TAT GAG TCC CAT TG
GTT GCC GGT ACA GTA AAT GC
GAA TGC CCA GGG CGA AAT AC
CAG CGA CTT GCC ATT GAG AC
AGC CAT TGC CTT TCG AGT AG
CGC CAA TTT CAG CCT TAG TG
CAG TAT CCG GAG TTG ATA GC
CCG CCA CTA TAT TCA ATC GC

788
bp
559
bp
272
bp
392
bp
170
bp
153
bp
1305
bp
119
bp
602
bp
328
bp
462
bp
586
bp
844
bp
908
bp
161
bp

cdt S1
cdt a1

GAAAGTAAATGGAATATAAATGTCCG
AAATCACCAAGAATCATCCAGTTA

430
bp

5‘at
94˚C

5‘ at
94˚C

5‘at
94˚C

5‘at
94˚C

25X (30‖ at
94˚C, 30‖ at
63˚C and
120‖ at
72˚C)

10‘at
72˚C

(Johnson
and Stell,
2000)

10‘at
72˚C

(Johnson and
Stell, 2000)

35X (30‖ at
94˚C, 30‖ at
53˚C and
90‖ at 72˚C)

10‘at
72˚C

(Toma et
al., 2004)

30X (30‖ at
94˚C, 30‖ at
50˚C and
60‖ at 72˚C)

7‘at
72˚C

(Allsopp et
al., 2012;
Allsopp et
al., 2010)

10‘at
72˚C

(Toma et
al., 2004)

25X (30‖ at
94˚C, 30‖ at
63˚C and
120‖ at 72˚C)

94˚C

35X (30‖ at
94˚C, 40‖ at
51˚C and
60‖ at 72˚C)

5‘at
94˚C

25X (30‖ at
94˚C, 30‖ at
˚C 63 and
60‖ at 72˚C)

10‘at
72˚C

(Johnson
and Stell,
2000)

35X (30‖ at
94˚C, 60‖ at
˚C 50 and
60‖ at 72˚C)

7‘at
72˚C

(Brisse et
al., 2009)

5‘at

Detection of Klebsiella pneumoniae virulence factors
mag A
allS

mag A-F
mag A-R
1416R
336F2

GGT GCT CTT TAC ATC ATT GC
GCA ATG GCC ATT TGC GTT AG
CCG TTA GGC AAT CCA GAC
TCT GAT TTA (A/T)CC CAC ATT

1280
bp
1090
bp

5‘at
94˚C

56

57
mrkD-1
mrkD-2
rmpA-F
rmpA-R
kfuB-F1179
kfuC-R649

TAT (T/C)G(G/T) CTT AAT GGC GCT GG
TAA TCG TAC GTC AGG TTA AAG A(C/T)C
ACT GGG CTA CCT CTG CTT CA
CTT GCA TGA GCC ATC TTT CA
GAA GTG ACG CTG TTT CTG GC
TTT CGT GTG GCC AGT GAC TC

920
bp
535
bp
797
bp

5‘at
94˚C

fim H

fim-1
fim-2

GCT CTG GCC GAT AC(C/T) AC(C/G) ACG G
GC(G/A)(A/T)A(G/A)TAACG(T/C) GCC TGG AAC
GG

423
bp

5‘at
94˚C

cf29a

cf29a-F
cf29a-R

GAC TCT GAT TGC ACT GGC TGT G
GTT ATA AGT TAC TGC CAC GTT C

862
bp

5‘at
94˚C

uge

uge-F
uge-R

GAT CAT CCG GTC TCC CTG TA
TCT TCA CGC CTT CCT TCA CT

534
bp

mrkD
rmp A
kfu BC

5‘at
94˚C

wabG

wabG-F
wabG-R

CGGACTGGCAGATCCATATC
ACCATCGGCCATTTGATAGA

683
bp

clp K

clpK-F
clpK-R

GGGGGGGGATCCGAACCTGCCTGACGACGCCAACCA
GGGGGGGTCGACGCAGCCTCGCCCGCCATCAAGA

437
bp

ure A

ureA-F
ureA-R

GCT GAC TTA AGA GAA CGT TAT G
GAT CAT GGC GCT ACC T(C/T) A

337
bp

5‘at
94˚C

Capsule
type K2
Capsule
type K5
Capsule
type K54
Capsule
type K57
Capsule
type K20

K2wzy-F1
K2wzy-R1
K5wzxF360
K5wzxR639
wzxK54F
wzxK54R
wzyK57F
wzyK57R
wzyK20F
wzyK20R

GACCCGATATTCATACTTGACAGAG
CCTGAAGTAAAATCGTAAATAGATGGC
TGGTAGTGATGCTCGCGA
CCTGAACCCACCCCAATC
CATTAGCTCAGTGGTTGGCT
GCTTGACAAACACCATAGCAG
CTCAGGGCTAGAAGTGTCAT
CACTAACCCAGAAAGTCGAG
CGGTGCTACAGTGCATCATT
GTTATACGATGCTCAGTCGC

641
bp
280
bp
881
bp
1037
bp
741
bp

5‘at
94˚C

5‘at
94˚C

35X (30‖ at
94˚C, 60‖ at
˚C 50 and
60‖ at 72˚C)
35X (30‖ at
94˚C, 60‖ at
˚C 55 and
60‖ at 72˚C)
35X (30‖ at
94˚C, 60‖ at
˚C 51 and
60‖ at 72˚C)

35X (30‖ at
94˚C, 60‖ at
˚C 53 and 60‖
at 72˚C)

35X (30‖ at
94˚C, 60‖ at
˚C 53 and
60‖ at 72˚C)
35X (30‖ at
94˚C, 60‖ at
˚C 55 and
60‖ at 72˚C)

35X (30‖ at
94˚C, 90‖ at
˚C 58 and
90‖ at 72˚C)

7‘at
72˚C

(Brisse et
al., 2009)

7‘at
72˚C

(Brisse et
al., 2009)

7‘at
72˚C

(Brisse et
al., 2009)

7‘at
72˚C

(Brisse et
al., 2009)

7‘at
72˚C

(Bojer et al.,
2010)

7‘at
72˚C

10‘at
72˚C

(Brisse et
al., 2009)

(Turton et
al., 2010)

57

58

wcaC
k.pneumoniae

16S-23S
ITS

wcaGF
wcaGR

GGTTGGKTCAGCAATCGTA
CTATTCCGCCAACTTTTGC

K.pneumoniae
Pf
K.pneumoniae
Pr1

ATTTGAAGAGGTTGCAAACGAT
TTCACTCTGAAGTTTTCTTGTGTTC

169
bp
130
bp

5‘at
94˚C

35X (30‖ at
94˚C, 90‖ at
˚C 58 and
90‖ at 72˚C)

10‘at
72˚C

(Turton et
al., 2010)

7‘at
72˚C

(Fang et al.,
2002)

Detection of disinfectant resistance genes
cepA

cepA-F
cepA-R

CAACTCCTTCGCCTATCCCG
TCAGGTCAGACCAAACGGCG

1051
bp

5‘at
94˚C

qac∆E1

qac∆E1_Zou-F
qac∆E1_Zou-R

AATCCATCCCTGTCGGTGTT
CGCAGCGACTTCCACGATGGGGAT

175
bp

5‘at
94˚C

qacE

qacE_Zou-F
qacE_Zou-R

AAGTAATCGCAACATCCG
CTACTACACCACTAACTATGAG

258
bp

5‘at
94˚C

qacF/H/I

qacF/H/I-F
qacF/H/I-R

GTCGTCGCAACTTCCGCACTG
TGCCAACGAACGCCCACA

229
bp

5‘at
94˚C

ydgE

qacG-F
qacG-R
emrE-F
emrE-R
mdfA-F
mdfA-R
sugE(c)-F
sugE(c)-R
sugE(p)-F
sugE(p)-R
ydgE-F
ydgE-R

TCGCCTACGCAGTTTGGT
AACGCCGCTGATAATGAA
TATTTATCTTGGTGGTGCAATAC
ACAATACCGACTCCTGACCAG
GCATTGATTGGGTTCCTAC
CGCGGTGATCTTGATACA
CTGCTGGAAGTGGTATGGG
GCATCGGGTTAGCGGACT
GTCTTACGCCAAGCATTATCACTA
CAAGGCTCAGCAAACGTGC
GGCAATCGTGCTGGAAAT
CGACAGACAAGTCGATCCCT

122
bp
195
bp
284
bp
226
bp
190
bp
149
bp

ydgF

ydgF-F
ydgF-R

TAGGTCTGGCTATTGCTACGG
GGTTCACCTCCAGTTCAGGT

330
bp

qacG
emrE
mdfA
sugE(c)
sugE(p)

5‘at
94˚C

30X (30‖ at
94˚C, 60‖ at
˚C 66 and
120‖ at
72˚C)
30X (30‖ at
94˚C, 30‖ at
˚C 56 and
30‖ at 72˚C)
30X (30‖ at
94˚C, 30‖ at
˚C 50 and
30‖ at 72˚C)
30X (30‖ at
94˚C, 35‖ at
˚C 60 and
60‖ at 72˚C)

30X (30‖ at
94˚C, 35‖ at
˚C 55 and
60‖ at 72˚C)

7‘at
72˚C

5‘at
72˚C

(Zou et al.,
2014)

5‘at
72˚C

5‘at
72˚C

(Zou et al.,
2014)

58

59

class I
Intragrase

intI-F2
intI-R2

GCT GCG TTC GGT CAA GGT TC
GCA CAG CAC CTT GCC GTA GA

256
bp

5‘at
94˚C

30X (45‖ at
94˚C, 45‖ at
˚C 56 and
45‖ at 72˚C)

5‘at
72˚C

(Lin et al.,
2009)

1‘at
72˚C

(Nakamura
et al., 2014)

1‘at
72˚C

(Nakamura
et al., 2014)

Detection of fosA& fosC
fosA

fosA3/4-fo
fosA3/4-re

TGA ATC ATC TGA CGC TGG
TCA ATC AAA AAA GAC CAT C

404
bp

5‘at
94˚C

fosC

fosC2-fo
fosC2-re

CGT TCC GTG GAG TTC TAT AC
CTT GAT AGG GTT TAG ACT TC

339
bp

5‘at
94˚C

30X (30‖ at
94˚C, 30‖ at
˚C 50 and
60‖ at 72˚C)
30X (30‖ at
94˚C, 30‖ at
˚C 53 and
60‖ at 72˚C)
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3.12 Plasmid Profile Analysis

For routine detection and isolation of large and small plasmids, the method of
Kado and Liu was used with minor modifications (Kado et al., 1981). The strains were
inoculated on TSA plates to obtain confluent growth and incubated overnight at 37oC.
Next day, cells were collected by toothpicks from an area of approximately 4 cm 2 and
suspended gently into 250 μl of lysing solution (3% SDS, 50 mM Tris, pH 12.57), and
mixed by gentle agitation until the suspension became homogenous and viscous. The
lysed cells were incubated at 60 °C in a thermoblock (Eppendorf) for 45 minutes with
gentle mixing every 15 minutes. After the incubation period, equal volume of 1:1
phenol:chloroform was added and the solution was emulsified by gentle shaking. The
emulsion was broken by centrifugation at 13,000 rpm for 15 minutes. The top aqueous
layer (approximately 60 μl) was transferred to clean tubes without disrupting the
precipitate at the interface. Samples were subjected to electrophoresis for 3 hours at 120
V in 0.8% agarose gel. The gels were stained with ethidium bromide, destained and
photographed using the Biometra gel documentation system.

3.13 Hybridization

Plasmid gels were de-purinated in 0.25 M HCl, followed by denaturation in 0.5
M NaOH, 1 M NaCl and finally neutralized in 1 M Tris, 0.6 M NaCl. All treatment steps
were 15 minutes long at room temperature with gentle shaking and were repeated twice.
Between each steps, gels were rinsed in sterile distilled water. The gel was capillarytransferred to Hybond N+ membranes (Roche) by soaking overnight in 20X SSC (saline
sodium citrate). Next day the membranes were UV cross-linked at 70,000 micro-joules.
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Hybridization probes were generated by PCR amplification of fosA3/A4 genes of
genomic DNA of strains KW11, followed by DNA purification (Promega kit, USA), and
quantitation using the ND-1000 spectrophotometer (Nano Drop Technologies, USA).
The DNA fragments were labeled using the DIG DNA labeling kit (Roche). In brief, 200
ng of purified fragment was boiled for 10 minutes in a boiling water bath and quickly
chilled on ice. The denatured DNA was conjugated with digoxigenin according to the
manufacturer‘s instructions. Membranes were pre-hybridized at optimal hybridization
temperature, which was calculated based on the size of the probe and GC ratio, using the
formula

recommended

by

the

manufacturer.

(Topt.=Tm-20oC

with

Tm=49.82+0.41(%G+C)-600/L (L=length of the probe in base pairs)) in a pre-warmed
hybridization buffer (5X SSC 1% blocking solution, 0.1 % N-lauryl sarcosine, 0.02%
SDS) for 30 minutes followed by the addition of the hybridization buffer containing the
probe. According to previous calculations, the membranes were hybridized overnight
with gentle shaking at 53oC.

For post hybridization, the blots were washed twice with 2X SSC/0.1% SDS
(Sigma) at room temperature (RT) for 5 minutes with gentle shaking followed by two
subsequent washings in 0.1X SSC/0.1 % SDS at 68oC for 15 minutes also with constant
agitation. The membrane was briefly rinsed in washing buffer at room temperature,
incubated in blocking solution for 30 minutes, and again incubated in antibody solution
provided with the kit for 30 minutes. The blots were washed twice in washing buffer,
equilibrated in detection buffer and finally incubated without shaking in the color
substrate solution for various lengths of time in the dark till the desired spot or band
intensity was seen. The reaction was stopped using TE buffer (10mM Tris, 1mM EDTA
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pH 8 (Sigma, USA)). The blot was digitized using the Biometra gel documentation
system.

3.14 Pulsed Field Gel Electrophoresis (PFGE)

We used the method of Gautom (Gautom, 1997). Briefly, bacterial strains grown
on TSA plates were suspended in 2ml of cell suspension buffer (100 mM Tris, 100 mM
EDTA, pH8.0) up to a density of 3 McFarland units. Suspensions were kept on ice.
Simultaneously, 1% plug (low melting point) agarose (Sigma, USA) was melted in 1%
SDS in TE buffer (10mM Tris:1mM EDTA pH 8) and kept at 54˚C. 500 μl bacterial
suspensions, 25 μl of proteinase K (Invitrogen) (20 mg/ml) and 525 μl of 1% plug
agarose were combined, mixed carefully, quickly transferred into 1 ml syringes and kept
for 15-30 minutes at room temperature to allow the solidification of the agarose.
Aliquots of 5 ml cell lysis buffer (50 mM Tris:50 mM EDTA pH 8, 1% Sarkosyl) and 25
μl of 20 mg/mL proteinase K were distributed into 50 ml tubes and 1mm thick slices of
agarose plugs were directly cut into them. They were incubated for 2 hours at 50˚C in a
shaker water bath (200 rpm). Subsequently, the plugs were washed twice with 10 ml of
preheated sterile MilliQ water for 20 minutes in a 50˚C shaker water bath. Plugs were
washed four times for 20 minutes with 10 ml of preheated TE buffer. Finally, plugs were
stored in 5 ml of fresh TE buffer at 4˚C.

Genomic DNA within the plugs was digested overnight at 37˚C in a 100 μl
restriction mixture made up of 10 μl of NE buffer 4 (New England Biolabs, UK), 1 μl of
BSA (New England Biolabs, UK), 30 U (1.5 μl) of XbaI enzyme (New England Biolabs,
UK) and 87.5 μl of sterile distilled water. Following digestion, the restriction mixtures

63

were removed and the plugs were incubated in 250 μl of 0.5X TBE buffer for 30
minutes at room temperature. Subsequently, plugs were inserted into wells of 1.4% of
agarose gel (Pulse Field Running Agarose A2929, Sigma, USA) prepared in 0.5xTBE
buffer. The two wells at the two sides of each gels contained a lambda-ladder PFGE
molecular mass marker (New England Biolabs, UK) for standardization. Gels were run
in CHEF Mapper (Biorad, USA) electrophoresis chamber in 0.5X TBE buffer prechilled to 14˚C. The running program consisted of 26 hours run at 6 V/cm with 120˚
angle and an initial switch time of 2.2 seconds and a final switch time of 54.2 seconds
with linear ramp.

The gels were stained with ethidium bromide for 20 minutes, followed by destaining in MilliQ water. Bands were detected and photographed under UV light in a
Biometra gel documentation system. Gel pictures were stored as .tif files for further
analysis. The GelCompare II software (Applied Maths, Sint-Martens-Latem, Belgium)
was used to analyze the banding patterns. The Unweighted Pair Group Method with
Arithmetic Mean (UPGMA) tree graphically showing the level of relatedness between
the isolates was created based on the Dice similarity coefficient (SD) (with a 1.5%
position tolerance). Depending of the specific tasks, strains showing patterns with SD ≥
80% or 90% were arbitrarily considered to represent a pulsotype.

3.15 Multilocus Sequence Typing (MLST)

In order to study the relatedness of the E. coli strains and K. pneumoniae strains,
their genomic DNA were typed by MLST method based on the protocol described by
Wirth et al. 2006 and Brisse et al. 2009, respectively (Brisse et al., 2009; Wirth et al.,
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2006). The seven housekeeping genes of E. coli (adk, fumC, gyrB, icd, mdh, pur, recA)
and the seven housekeeping genes of K. pneumoniae (ropB, gapA, mdh, pgi, phoE, infB,
tonB) were amplified by the primers shown in Table 7. In some cases the MLST typing
was carried out commercially (ID Genomics, Seattle, WA, USA) for which we provided
purified genomic DNA.

E. coli isolates were assigned to sequence types using the tools on the E. coli
MLST webpage (http://mlst.ucc.ie/mlst/dbs/Ecoli). For K. pneumoniae the MLST
webpage (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html) was
used.

3.16 Sequencing

PCR products were purified either by the EXO-SAP or PCR purification kit
(QIAGEN, Germany) prior to sequencing. Sequencing was done using the Big Dye
Cycle Terminator V.3.1 (Applied Biosystems, USA) according to the manufacturer's
instructions. The samples were sequenced in both directions using the 3130X Genetic
Analyzer (Applied Biosystems, USA). Sequences were analyzed using the MEGA5
(http://www.megasoftware.net/mega4/mega.html)
Edsoftware) software.

and

the

Clone

Manager

(Sci-
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3.17 ERIC PCR

The Enterobacterial Repetitive Intergenic Consensus Polymerase Chain Reaction
(ERIC-PCR) (Versalovic et al., 1991) method was used to rapidly confirm differences
between donor and recipient strain for conjugation and/or transformation. It was
performed by using the ERIC2 primer (5‘-AAG TAA GTG ACT GGG GTG AGC G3‘). A 7-minute initial denaturation at 94˚C was followed by 30 cycles of denaturation
for 30 seconds at 90˚C, annealing for 60 seconds at 50˚C and extension for 8 minutes at
65˚C. The final step was an extension for 16 minutes at 65˚C. The patterns obtained with
different strains (strictly amplified in the very same experiment only) were compared
visually.

3.18 Statistical Analysis

If clustering was considered extensive, to investigate the association between
groups of strains and specific features, we used the generalized linear mixed effect
model (GLMM) with a binomial distribution (Breslow and Clayton, 1993). This model
is used to take into account the potential correlation that may occur between members in
the same family. We used the R software version 3.2.2 for data analysis (Team, 2014).
The function glmmPQL (Breslow and Clayton, 1993; Schall, 1991) from the package
MASS was used to fit the GLMM model with binomial distribution for our data. This
analysis was kindly carried out by Dr. Abderrahim Oulhaj, Institute of Public Health,
CMHS, UAEU. For assays not affected by clustering, Fisher‘s exact test and the Student
t test were used.
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Chapter 4: Results

4.1 Characterization of Blood Stream E. coli Isolates Recovered in the UAE

4.1.1 General Characteristics of the Collection
Altogether, 172 Escherichia coli bloodstream isolates, all independent and
clinically relevant strains recovered at Tawam Hospital, Al Ain, UAE between 2010 and
2011 were included in the study. The basic demographic and clinical data available are
summarized in Table 8. No further details on the patients and on the clinical details, i.e.
nationality, outcome etc., were available.
Table 8: Demographic and basic clinical data
Specifics
n

172

Age (x ± SD)

51.9±26.1

Male: Female ratio

88:84

Malignancy present

n (%)

72 (41.9)

Of these solid tumor

n (%)

49 (68.1)

Hematological malignancy n (%)

23 (31.9)

Urosepsis* n (%)

64 (37.2)

Line infection n (%)

10 (5.81)

*As substantiated by simultaneous E. coli isolated from the urine
(strains from urine were not available to compare to blood isolate)
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PFGE studies of the 167 (97.1%) typable isolates revealed a heterogeneous
population exhibiting 98 distinct PFGE patterns even if (SD ≥80%) coefficient was used
as a similarity threshold (Figure 5.). The clustering is shown in Table 9.

Figure 5: Pulsed Field Gel Electrophoresis patterns of the isolates
The dashed line represent the threshold of 80% similarity, red boxes identify clusters

Table 9: Cluster size distribution of the isolates
Size of the cluster (No. of isolates in cluster)
No. of
1

2

3

4

5

6

7

8

54

30

10

1

1

1

0

1

clusters
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4.1.2 Antibiotic Susceptibility

The antibiotic resistance of the isolates was assessed by disc diffusion and the
results, together with the rate of ESBL production, are summarized in Table 10.

Table 10: Antibiotic Resistance of the Isolates

Antibiotic
AP
AUG
CIP
CAZ
CPD
CTX
CXM
FOX
TIM
PTZ
ERT
IMP
MEM
DXT
CHL
GN
AK
NET
SXT
ESBL production

Resistant
(%)
75.6
18.6
47.1
26.7
36.0
39.5
37.2
4.7
33.1
8.1
0.6
0.0
0.0
55.2
13.4
21.5
2.9
5.8
55.8

Intermediate
(%)
0.0
27.9
5.8
3.5
9.3
11.0
2.9
2.3
20.3
14.0
0.6
0.6
0.0
8.1
1.2
0.6
5.2
5.2
1.2
32.6

AP-Ampicillin, AUG-Augmentin, CIP-Ciprofloxacin, CAZ-Ceftazidime, CPDCefpodxim,
CTX-Cefotaxime,
CXM-Cefuroxime,
FOX-Cefoxitin,
TIMTicracillin/clavulanic acid, PTZ-Pipracillin-tazobactam, ERT-Ertapenem, IMPImipenem, MEM-Meropenem, DXT-Doxycycline, CHL-Chloramphenicol, GNGentamicin, AK-Amikacin, NET-Netilmicin, SXT-Trimethoprim-Sulphamethoxazole.
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In nearly one third of the isolates (32.6%) ESBL production was detected by the
key-hole test. In all 56 ESBL producing strains the enzyme was of the CTX-M type.
Within this group, with the exception of 6 blaCTX-M-27 and 1 each of blaCTX-M-1 and
blaCTX-M-14, all others represented blaCTX-M-15. The resistance to 3rd and 4th generation
cephalosporins reflected this ratios (Table 10). One strain, carrying the blaOXA-48-like
carbapenemase gene exhibited resistance to ertapenem, while two others were not fully
susceptible to carbapenems. One exhibited intermediate susceptibility to ertapenem,
while another exhibited intermediate susceptibility to meropenem,. These two also did
not show any carbapenemase activity, and common carbapenemase genes were not
detected within them.

The high rate of resistance (exceeding 50%) to doxycycline and trimethoprimesulphamethoxasole, and similarly high resistance rate to ciprofloxacin (47.1%) was
noteworthy. While only a few strains carried plasmid-associated qnrA, B, S and qepA
genes (1, 4, 2 and 4 strains, respectively), 69 of them harbored acc (6’)-Ib-cr exhibiting a
strong correlation between this gene and resistance to ciprofloxacin (P<0.0001) (data not
shown).

4.1.3 Phylogentetic Groups, Core Types and Virulence Factors

The rate of the different phylogenetic types, core type and virulence factors are
shown in Table 11.
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Table 11: Phylogenetic groups distribution, core types and virulence factors of the
strains
Specifics
Phylogenetic Groups

n (%)
A
B1
B2
D

31 (18.02)
22 (12.79)
69 (40.12)
50 (29.07)

R1
R2
R3
R4
K-12

58 (33.72)
14 (8.14)
31 (18.02)
30 (17.44)
39 (22.67)

Core Types

Virulence Factors
PAI
hlyA
sat
CDT
Cnf1
tox B
paP C
paP AH
paP EF
tra T
ibe A
cva C
fim H
bma E
sfa/foc DE
foc G
sfaS
gaf D
nfa E
afa/dra
iha
upa B
upa H
usp
ire A
iro N
fyu A
iut A

79 (45.93)
34 (19.77)
72 (41.86)
0 (0.00)
23 (13.37)
0 (0.00)
59 (34.30)
60 (34.88)
57 (33.14)
123 (71.51)
2 (1.16)
15 (8.72)
154 (89.53)
2 (1.16)
18 (10.47)
9 (5.23)
5 (2.91)
2 (1.16)
3 (1.74)
18 (10.47)
51 (29.65)
79 (45.93)
68 (39.53)
96 (55.81)
24 (13.95)
55 (31.98)
129 (75.00)
121 (70.35)
Cont.
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Cont.
rfc
KpsMT III
KpsMT II
K1
K5
Virulence factor score (x ± SD)

2 (1.16)
10 (5.81)
92 (53.49)
20 (11.63)
54 (31.40)
8.45 ± 4.6

The high frequency of core types R4 and K-12 was surprising as these core types
are usually rare among ExPEC (Amor et al., 2000; Appelmelk et al., 1994; Gibb et al.,
1992). Furthermore, as the rate of strains belonging to phylogenetic group D was higher
than reported earlier for bloodstream isolates (Szijártó et al., 2012), we analyzed these
features with attention focused on these two groups ( Tables 12.).

Table 12: Distribution of phylogenetic groups within different core types

Core type

n

R1

58

R2

14

R3

31

R4

30

K-12

39

Phylogenetic group

n (%)

A

B1

B2

D

12
(20.7)
14
(100.0)
2
(6.5)
2
(6.7)
1
(2.6)

14
(24.1)
0
(0.0)
7
(22.6)
1
(3.3)
0
(0.0)

29
(50.0)
0
(0.0)
2
(6.5)
1
(3.3)
37
(94.9)

3
(5.12)
0
(0.0)
20
(64.5)
26
(86.7)
1
(2.6)
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The analysis clearly showed that more than half of the group D strains had R4
core type genes and nearly 90% of the strains carrying this core type belonged to group
D, showing a highly significant correlation between and R4 core type and group D
(P<0.0001) (Table 12.). Furthermore, more than half of the B2 strains carried a K-12
core and nearly all (94.9%) K-12 core type strains belonged to the B2 phylogenetic
group. Only 1-1 strains belonged to groups A and D (Table 12.), also indicating a very
strong correlation between the K-12 core structure and the B2 group (P<0.0001).

Taking PFGE clustering into consideration when conducting statistical analysis
the following features exhibited association at varying levels of significance (P≤0.05)
with strains of different core types (Table 13.).

Table 13: Significant association of specific features with core types

Core
type

Feature with significant (P=>0.05) association
n
Source

Genotype
qnrB, iroN, ireA, usp,
upaH, upaB, sfa-foc-DE,
cvaC, PaPAH, PaPEF,
cnf1, HlyA
K5, KpsMTII, KpsMTIII,
iha

R1

58

-

R2

14

-

R3

31

Line infections

R4

30

Line infections,
malignancy,
solid tumors

K5, KpsMTII,

K-12

39

Urosepsis

acc (6’)-Ib-cr, K5,
KpsMTII, traT, PaPEF,
PaPC, PAI

Nonsusceptibility
-

CTX, CAZ, GN
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4.1.4 Characterization of B2/K-12 and D/R4 Strains

Next, the homogeneity of the group B2/core K-12 strains (n=37) and that of the
group D/R4 strains (n=26) was investigated by determining their MLST. The results are
shown in Table 14.

Table 14: Distribution of sequence types among strains with rare phylogenetic group/
core type combinations

Strain
type*

n

Sequence type n (% within strain type)

% of
all

B2/K-12

37 21.51

D/R4

26 15.11

ST

ST 38

ST 131

ST 362

ST 405

ST 648

0

37

0

0

0

0

(0.00)

(100.00)

(0.00)

(0.00)

(0.00)

(0.00)

8

0

1

7

9

1

(30.76)

(0.00)

(3.84)

(26.92)

(34.61)

(3.84)

1882

*phylogeny group/core type
While the association of the ST131 type with the K-12 core type was anticipated
from our previous studies (Szijártó et al., 2012), the link of other common ExPEC clones
to a previously relatively rare core type needed further confirmation. In order to validate
our PCR results suggestive of R4 core type in strains belonging to these three common
MDR STs the entire sequence of the outer core oligosaccharide operon (GenBank
AF019747,1 (Heinrichs et al., 1998) was blasted against the whole-genome shotgun
contigs (wgs) available in the NCBI database (Kindly carried out by Dr. Valeria
Szijartó, Arsanis, Vienna, Austria). On the first 100 whole genome sequences showing
100% coverage and a minimum of 99% identity with the query sequence multilocus
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sequence typing (MLSA) was performed in silico. Of these 21, 20 and 18 belonged to
ST38, ST405 and ST 648, respectively, i.e., to the STs identified as carrying the R4 core
type in the current study (Table 14.).

Next, to study the internal structure of these clones their PFGE patterns were reanalyzed omitting any isolates with different STs and using the stricter SD≥90%
similarity threshold. Also, macrorestriction patterns of strains not belonging to any of
these STs (i.e. ST38, ST131, ST405 and ST648) were also re-analyzed as one group.
The data are presented in Figures 6.-10. and Table 15.

Figure 6: Macrorestriction patterns of ST38 isolates
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.
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Figure 7: Macrorestriction patterns of ST131 isolates
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.

Figure 8: Macrorestriction patterns of ST405 isolates
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.
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Figure 9: Macrorestriction patterns of ST648 isolates
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.

Figure 10: Macrorestriction patterns of isolates not belonging to the four MDR STs
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.
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Table 15: Cluster size distribution of strains within and outside the MDR STs
STs

n*

Number of
patterns

Number of clusters containing members
of
1

2

3

ST38

8

7

6

1

0

ST131

37

29

21

8

0

ST405

5

4

3

1

0

ST648

9

9

9

0

0

Others

108

97

91

4

2

n* - No. of typable strains
These data showed that within the clonal group ST131 strains and, particularly
strains beyond the 4 major STs were, as expected, rather heterogeneous.

The strains belonging to these 4 STs were considerably more resistant than the
other isolates combined. The rates of resistance to selected antibiotics within these STs,
as compared to other isolates and shown in Figure 11. The resistance rates against all
these antibiotics were significantly higher in the group combining the emerging STs
compared to strains outside of these sequence types (P<0.01), although variations among
the four STs existed, particularly when none-ß-lactams were considered. For instance,
strains in the ST38 group exhibited similarly low rates of resistance against
ciprofloxacin and gentamicin as the strains outside these STs did, while among members
of the other 3 STs resistance even to these drugs was very common.
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Figure 11: Rate of resistance to selected antibiotics within and outside of the common
sequence type
CXM – cefuroxime, CTX – cefotaxime, CAZ – ceftazidime, CPD – cefpodoxim, CIP –
ciprofloxacin, GN – gentamicin, SXT – trimethoprim-sulphamethoxazole, DXC –
doxycycline. MDR STs – strains belonging to either ST38, 131, 405 or 648 sequence
types. Others – strains beyond these STs.
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Summarizing the characteristics of the clones, Table 16. shows that while they
were more resistant than other isolates, with the exception of the ST131 clone, they
carried less virulence-related genes.
Table 16: Characteristics of the four common clones
ST

Phylogeny

Core

ST131

B2

K-12

ST38

D

R4

ST405

D

R4

ST648

D

R4

All
others

Mixed

Mixed

Nonsusceptibility*
CXM, TIM,
DXT, SXT, AP,
CIP, CAZ,
CPD, CTX,
CXM, TIM,
DXT, SXT, AP,
AUG, CIP,
CAZ, CPD,
CTX,
CXM, FOX,
TIM, PTZ,
DXT, SXT, AP,
AUG, CIP,
CAZ, CPD,
CTX,
CXM, TIM,
PTZ, DXT,
SXT, AP,
AUG, CIP,
CAZ, CPD,
CTX,
DXT, AP

Genotype*

Virulence
score**

Acc (6’)-Ib-cr, PAI,
traT, fimH, iha,
upaB, upaH, usp,
fyuA, iutA, KpsMTII

11.22 ± 1.83

traT, fimH, usp,
fyuA, iutA, KpsMTII,

6.88 ± 2.3

Acc (6’)-Ib-cr, traT,
fimH, fyuA,
KpsMTII, k5

5.43 ± 0.98

Acc (6’)-Ib-cr, traT,
fyuA, iutA, KpsMTII,

4.44 ± 1.81

traT, fimH, fyuA,
iutA,

8.15± 5.14

* Feature or gene present in at least 50% of the isolates
**The average number of virulence genes present/strain
Taken together, our results showed that three of the recently emerging ExPEC
clones (ST38, ST405 and ST648) carry a core type previously relatively rarely
encountered among bloodstream isolates. These clones, while highly resistant, were less
virulent that other strains.

80

4.2 Characterization of Carbapenem Resistant Klebsiella pneumoniae (CRKP)
Clones and Sporadic Isolates Recovered in the Arabian Peninsula

4.2.1 Identification of Clones
Our laboratory received 165 CRKP strains between 2011 and 2013 from various
countries from the Arabian Peninsula to determine their carbapenemase types. All
repeated isolates were eliminated from the same patients. Additionally, few isolates
carrying the blaVIM carbapenemase gene were also eliminated since they were
encountered rarely. The distribution of the strains according to country, specimen type
and the carbapenemase carried is shown in Table 17.

Table 17: Origin, source and carbapenemases produced by CRKP
%

Country of origin

UAE
KW*
OM**
KSA

38.8
7.9
25.5
27.9

Specimen type

Blood
Respiratory
Urine
Wound
Screening ***
Others

13.9
33.3
20.0
17.6
10.9
4.2

Carbapenemase produced

NDM
OXA-48-like
NDM-OXA
None

49.1
31.5
10.3
9.1

* KW-Kuwait
** OM-Oman
*** Screening- Infection control screening samples

81

In order to assess any clustering within this pool of isolates, they were subjected
to macrorestriction analysis using a tolerant, (SD >80%) similarity threshold. The PFGE
patterns of the isolates are shown on Figure 12.

Of the 165 isolates, 163 (97.8%) were typable. The strains exhibited 70 PFGE
types. The cluster distribution is shown in Table 18.

Table 18: Distribution of PFGE clusters
Size of cluster (n)

Number of
clusters

1

2

3

7

9

11

15

23

38

21

6

1

1

1

1

1

In order to establish clonal groups, strains were subjected to multi-locus
sequence typing (MLST). For PFGE clusters, the following approach was applied: for
each cluster up to 3 members at least one strain with each specific carbapenemase
production type was MLST-ed. For larger clusters, the same rule was applied with larger
numbers (i.e., usually 2-4 for each carbapenemase type, if present) of strains tested.
Sequence types differing in a single allele only were assigned to clonal groups as shown
in Table 19. Strains with the same sequence type or within the same clonal complex
were considered a clone if containing more than 3 members. Strains outside of clones
were considered sporadic. By these rules, 2 sequence types and 4 clonal complexes were
identified to represent clones (Table 19).
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Figure 12: PFGE clusters of the 163 K. pneumoniae isolates
The dashed line represent the threshold of 90% similarity, red boxes identify clusters.
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Table 19: Allele types of clonal complexes and sequence types
CC** ST***
11
15

17

147
-

11
340
14
15
709
16
17
336
2103
147
273
392
101
152

gapA
3
3
1
1
1
2
2
2
2
3
3
3
2
2

infB
3
3
6
1
1
1
1
1
1
4
4
4
6
3

Allele types*
mdh
pgi
phoE
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
4
1
1
4
1
1
72
1
1
13
6
1
7
6
1
7
6
1
7
1
5
4
2
1
1

rpoB
1
1
1
1
1
4
4
4
4
4
4
4
1
4

tonB
4
18
1
1
4
4
4
4
4
38
4
40
6
56

*Numbering of alleles is according to the Klebsiella pneumoniae MLST website
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html).
Boxes indicate allele differences within clonal complexes
** CC- Clonal Complex they are differing in 1 allele, only
*** ST- Sequence Type is a unique string of numbers

4.2.2 General Characterization of the Clones

The distribution of country of origin and specimen type of the clones they were
recovered from are shown in Tables 20. and 21. It should be noted that there were clones
represented by strains isolated in multiple countries.

As can be seen, representatives of all clones had been recovered from multiple
specimens, for most also including screening samples. It was noteworthy that the bloodstream isolates were absent in the two smallest clones, only.
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Table 20: Country of origin of the clones
Groups

n

All
CC11
CC15
CC17
ST101
CC147
ST152
Sporadic

165
20
37
7
5
30
23
43

Country of origin (%)
UAE
KW*
OM**
38.8
7.9
25.5
35.0
0.0
55.0
75.7
5.4
10.8
0.0
57.1
0.0
40.0
0.0
0.0
23.3
6.7
50.0
0.0
0.0
0.0
46.5
11.6
27.9
* KW-Kuwait
** OM-Oman

KSA
27.9
10.0
8.1
42.9
60.0
20.0
100.0
14.0

Table 21: Distribution of the strains assigned to clones according to the types of
specimen
Groups
All
CC11
CC15
CC17
ST101
CC147
ST152
Sporadic

Specimen types (%)
n
165
20
37
7
5
30
23
43

Blood
13.9
25.0
18.9
0.0
0.0
16.7
4.3
11.6

Resp
33.3
20.0
24.3
42.9
60.0
23.3
78.3
25.6

Urine
20.0
20.0
24.3
28.6
20.0
20.0
13.0
18.6

Wound
17.6
15.0
16.2
14.3
0.0
23.3
4.3
25.6

Screening*
10.9
15.0
16.2
14.3
20.0
13.3
0.0
7.0

Others
4.2
5.0
0.0
0.0
0.0
3.3
0.0
11.6

*Screening- Infection control screening samples

4.2.3 Comparison of Carbapenemases Produced by Clones and Sporadic Isolates

The type of carbapenemase produced by clones and sporadic isolates is shown in
Table 22. It was noteworthy that all clones carried blaNDM as a single carbapenemase
gene at a higher, and with the exception of CC17, blaOXA-48-like at a lower rate than did
sporadic isolates. For the four more frequently observed clones, where statistical
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analysis was possible, the higher rate of NDM carriage significantly exceeded that found
among sporadic isolates (Fisher test, P varying between 0.0268 and <0.0001).
Conversely, with the exception of clone C11 (P=0.2838) the rate of blaOXA-48-like
carriership was significantly less common among members of the larger clones.

Table 22: Carbapenemase genes in the strains assigned to clones
Groups

n

All
CC11
CC15
CC17
ST101
CC147
ST152
Sporadic

165
20
37
7
5
30
23
43

NDM
49.1
55.0
43.2
28.6
40.0
66.7
95.7
18.6

Carbapenemase (%)
OXA
NDM-OXA
31.5
10.3
35.0
5.0
27.0
24.3
71.4
0.0
40.0
0.0
20.0
10.0
0.0
4.3
51.2
7.0

None
9.1
5.0
5.4
0.0
20.0
3.3
0.0
23.3

Another noteworthy observation was that the rate of strains without detectable
carbapenemase genes was considerably higher in the sporadic group than among the
clones identified. The differences, regarding the large clones, with the exception of
CC11 (P=0.1505) did even reach the level of statistical significance (P varying between
0.0124 and 0.0308).

The PFGE cluster distribution within the clones is shown in Figures 13.-18.
together with the carbapenemases produced. The cluster structure of the clones is
presented in Table 23. The homogeneity of the clones varied with ST152 being the most
homogenous. This was supported by the approximate value of variability comparing the
size of a clone to the number of clusters present within Table 23. It was also noteworthy
that in all clones strains producing different carbapenemase, at least in addition to the
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one dominating in the particular clone (see NDM, NDM and OXA in ST152) were
present. As expected, sporadic isolates were highly heterogeneous (Figures 19.).

Figure 13: PFGE clusters of CC11 strains

Figure 14: PFGE clusters of CC15 strains
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Figure 15: PFGE clusters of CC17 strains

Figure 16: PFGE clusters of ST101 strains

Figure 17: PFGE clusters of CC147 strains

88

Figure 18: PFGE Clusters of ST152 strains

Figure 19: PFGE clusters of sporadic strains
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Table 23: Cluster structure of clones and sporadic strains
Groups

n

Number of
patterns

Variability©

Size of clusters (n)

CC11

20

15.0

1.33

1 2 3 4 6 13 15
12 2 0 1 0 0 0

CC15

37

18.0

2.06

14 3 0 1 0

1

0

CC17

7

5.0

1.40

3

2 0 0 0

0

0

ST101

5

4.0

1.25

3

1 0 0 0

0

0

CC147

30

21.0

1.43

16 4 0 0 1

0

0

ST152

23

4.0

5.75

2

1 0 1 0

0

1

Sporadic

41*

39.0

1.05

37 2 0 0 0

0

0

*2 out of the 43 strains were non-typable. © defined as n/patterns

4.2.4 Virulence of Clones and Sporadic Isolates
The results of testing the presence of 16 virulence-related genes in the isolates
are summarized in Table 24.

Table 24: Frequencies of virulence-related genes in the isolates
Genes

Frequency of virulence genes (%) in
All

CC11

CC15

CC17

ST101

CC147

ST152

Sporadic

fyuA

52.7

25.0

83.8

14.3

80.0

30.0

78.3

44.2

iutA

2.4

0.0

2.7

0.0

0.0

0.0

0.0

7.0

ireA

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

iroN

3.6

5.0

0.0

14.3

0.0

3.3

0.0

7.0

kfuBC

26.7

15.0

89.2

0.0

40.0

3.3

0.0

11.6

magA

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

allS

1.8

0.0

0.0

0.0

0.0

0.0

0.0

7.0

cf29A

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

mrkD

95.8

100.0

97.3

100.0

100.0

93.3

100.0

90.7
Cont.

90

Cont.
fimA

98.8

100.0

100.0

100.0

100.0

96.7

100.0

97.7

rmpA

1.2

0.0

0.0

0.0

0.0

0.0

0.0

4.7

ugeA

98.8

100.0

100.0

100.0

100.0

96.7

100.0

97.7

wabG

90.9

80.0

94.6

100.0

80.0

86.7

95.7

93.0

cnf1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

traT

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

clpK

43.0

60.0

81.1

71.4

20.0

6.7

8.7

44.2

Strains in all groups, including the sporadic isolates contained almost uniformly,
the biofilm formation-linked type 3 fimbria gene mrkD, the adhesion-related type 1
fimbria gene fimA and the ugeA and wabG genes associated with the synthesis of cell
wall. Considerable variations between groups were observed regarding the presence of
fyuA, kfuBC and clpK genes. Some of the clones carried these genes at much higher
frequencies than the sporadic isolates (e.g. CC15, ST152 for yersiniabactin iron binding
outer membrane protein fyuA, and iron uptake related kfuBC genes, or CC11, CC15 for
heat-shock resistance associated clpK genes). On the other hand, for some other clones
the very opposite trend could be observed, i.e., they carried these genes at a lower rate
than their sporadic counterparts (e.g. CC11 and CC147 for fyuA, ST152 for kfuBC, or
CC147 and ST152 for clpK, respectively).

When the combined impact of virulence-related genes was investigated by
comparing the virulence scores (i.e. the sum of positive virulence gene PCRs) between
the groups, it was found that only CC15 strains had a considerably higher score than
sporadic isolates (P=<0.0001) and in case of CC147 it was even significantly lower
(P=0.0009) Table 25.

91

Similarly varying results were obtained when investigating the serum sensitivity
of the isolates. Comparing the actual survival rate after 3 hours of serum exposure did
not show any significant differences between sporadic strains and the larger clones,
although the rate of strains sensitive to serum was more common among sporadic strains
(Table 25.).

Regarding biofilm production, in general, most strains were commonly
producing strong biofilms. The rate of strong producers was the lowest among sporadic
strains but even among them is was almost 75% (Table 25.). The optical densities
indicating the amount of attached bacteria in the biofilm matt were significantly higher
for CC15 and CC147 strains (P=0.0226 and P<0.0001, t-test). Moderate to nonproducers occurred in every clone with the exception of the small (n=7) CC17 where all
isolates produced a strong biofilm.

Importantly, only 5 isolates of the entire collection, 2 among CC11, in CC15, 1
in CC17 and 1 among the sporadic strains exhibited the hyperviscous phenotype
characteristic to highly invasive strains (Shon and Russo, 2012).
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Table 25: Virulence-related features of the strains

Groups

n

Virulence
score

All

165

5.16 ± 1.23

Serum
survival
rate
1.21 ± 2.68

CC11

20

4.85 ± 0.99

0.68 ± 1.29

15

20

1.26 ± 0.53

85

15

0

0

CC15

37

6.49 ± 0.93

0.70 ± 1.09

27

24.3

1.63 ± 0.85

81.1

2.6

16.2

0

CC17

7

5.0 ± 0.00

0.08 ± 0.16

0

57.1

1.51 ± 0.41

100

0

0

0

ST101

5

5.2 ± 1.48

8.39 ± 10.49

60

20

1.17 ± 0.65

80

0

0

20

CC147

30

4.17 ± 0.99

1.50 ± 2.81

43.3

3.3

2.08 ± 0.75

96.7

0

0

3.3

ST152

23

4.83 ± 0.65

1.45 ± 1.29

69.6

8.7

1.32 ± 0.68

91.3

4.3

0

4.3

Sporadic

43

5.05 ± 1.11

0.9 ± 1.58

27.9

32.6

1.24 ± 0.63

74.4

16.3

7

2.3

Rate (%) of serum

Rate (%) of biofilm formation

Sensitive

Biofilm
OD570±SD

Strong

Moderate

Weak

None

34.5

21.2

1.5 ± 0.75

84.8

7.3

5.5

2.4

Resistant
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4.2.5 Antibiotic Resistance of Clones and Sporadic Isolates

The antibiotic susceptibility of sporadic isolates and strains within clones were
also compared. Regarding ß-lactam drugs, with the exception of CC17, i.e,. one of the
two smaller clones, no real differences were noted regarding the MIC values. While
being above the clinical breakpoint (i.e. ≥ 2 mg/L), CC17 strains had a considerably
lower MIC50 value compared to some of the other clones, reaching 64 mg/L against
ertapenem (Table 26.).

The rate of resistance to the different antibiotics was also established (Table 27.).
As expected (considering the selection criteria of the strains, i.e., being non-susceptible
to at least one carbapenem), the rate of resistance to any ß-lactam drugs at least
approached 100% in all groups. However, a much less uniform picture emerged when
comparing the resistance rates to non-beta lactam antibiotics (Table 27.).
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Table 26: MIC values of antibiotics against the different clones

MIC (mg/L) against different groups (n)
Antib.

ERT

IMP

MEM

CAZ

CTX

AZT

TGC

COL

Range

All

CC11

CC15

CC17

ST101

CC147

ST152

Sporadic

(165)

(20)

(37)

(7)

(5)

(30)

(23)

(43)

MIC50

16

32

64

8

64

16

16

16

MIC90

64

64

64

TFC

TFC

64

32

16

MIC50

8

8

16

8

8

8

16

8

MIC90

64

32

64

TFC

TFC

64

32

32

MIC50

32

64

128

16

64

32

32

32

MIC90

128

128

128

TFC

TFC

128

128

128

MIC50

128

128

128

128

128

128

128

128

MIC90

128

128

128

TFC

TFC

128

128

128

MIC50

128

128

128

64

128

128

128

128

MIC90

128

128

128

TFC

TFC

128

128

128

MIC50

128

128

128

64

128

128

128

128

MIC90

128

128

128

TFC

TFC

128

128

128

MIC50

1.5

1

2

1

1

2

1

1.5

MIC90

4

2

6

TFC

TFC

6

1

4

MIC50

0.19

0.125

0.19

0.25

0.125

0.19

0.19

0.19

MIC90

0.5

0.5

4

TFC

TFC

6

0.38

0.5

TFC – Too few to calculate
ERT- Ertapenem, IMP- Imipenem, MEM- Meropenem, CAZ-Ceftazidime, CTXCefotaxime, AZT- Aztreonam, TGC- Tigecycline, COL- Colistin
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Table 27: The rate of resistance to antibiotics

Rate (%) of resistance in groups (n)
Antibiotics

All

CC11

CC15

CC17

ST101

CC147

ST152

Sporadic

(165)

(20)

(37)

(7)

(5)

(30)

(23)

(43)

ERT

100.0

100.0

100.0

100.0

100.0

100.0

100.0

100.0

IMP

93.9

100.0

94.6

100.0

80.0

100.0

100.0

83.7

MEM

99.4

100.0

100.0

100.0

100.0

100.0

100.0

97.7

CAZ

94.5

95.0

97.3

85.7

100.0

96.7

100.0

88.4

CTX

95.2

95.0

97.3

85.7

100.0

96.7

100.0

90.7

AZT

87.9

95.0

91.9

71.4

100.0

80.0

95.7

83.7

TGC

23.6

5.0

37.8

14.3

0.0

43.3

0.0

23.3

COL

7.3

5.0

10.8

0.0

20.0

13.3

4.3

2.3

CIP

92.7

100.0

100.0

71.4

100.0

100.0

100.0

76.7

SXT

83.0

90.0

83.8

85.7

80.0

80.0

100.0

72.1

GN

76.4

85.0

89.2

14.3

100.0

86.7

100.0

48.8

AK

55.8

45.0

62.2

42.9

60.0

70.0

100.0

23.3

TOB

86.7

95.0

91.9

71.4

80.0

96.7

100.0

67.4

CHL

49.1

65.0

70.3

28.6

0.0

83.3

4.3

32.6

DXT

58.8

60.0

51.4

71.4

80.0

63.3

47.8

62.8

ERT- Ertapenem, IMP- Imipenem, MEM- Meropenem, CAZ-Ceftazidime, CTXCefotaxime, AZT- Aztreonam, TGC- Tigecycline, COL- Colistin, CIP- Ciprofloxacin,
SXT- Trimethoprim-Sulphamethoxazole, GN- Gentamicin, AK- Amikacin, TOBTobramycin, CHL- Chloramphenicol, DXT- Doxycycline

With a few exceptions, notably the relatively sensitive small clone, CC17, the
rate of resistance to non-ß-lactam drugs was considerably higher among the clones than
among sporadic isolates. This was particularly obvious in case of colistin, ciprofloxacin
and aminoglycoside antibiotics, e.g., gentamicin, amikacin and tobramycin, respectively
(Table 27.).
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The difference between clonal and sporadic strains were even more obvious
when the results were expressed as a ―resistance score‖, defined as the number of drugs
a strain expressed resistance to (Table 28.).

Table 28: Resistance scores of the groups
Resistance score
N of

All antibiotics

Non-ß-lactam antibiotics

strains

(n=15)

(n=9)

All

165

11.04 ± 2.09

5.33 ± 1.72

CC11

20

11.35 ± 1.69

5.5 ± 1.15

CC15

37

11.78 ± 1.16

5.97 ± 1.07

CC17

7

9.43 ± 1.72

4.00 ± 0.82

ST101

5

11.0 ± 1.0

5.2 ± 1.1

CC147

30

12.10 ± 1.88

6.37 ± 1.71

ST152

23

11.52 ± 0.67

5.57 ± 0.59

Sporadic

43

9.53 ± 2.68

4.09 ± 2.11

As seen, members of all clones, with the exception of the small CC17, were more
resistant to antibiotics, and notably more non-ß-lactam antibiotics, than the sporadic
isolates, which, in case of the larger clones analyzed, reached the level of statistical
significance (P between 0.0072 and <0.0001).

These findings were in line with our results regarding the presence of noncarbapenemase-coding resistance genes. With the exception of the low rate of blaTEM
seen in the small clone ST101, TEM, SHV and CTX-M coding genes were commonly
present in each groups. However, testing a limited number of fluoroquinolone and
aminoglycoside resistance genes showed that sporadic strains less commonly carried
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these genes than, with the exception of the small CC17 clone, their clonal counterparts
(Table 29.). This was particularly noteworthy when the comparison regarding the
presence of any 16S methylases causing broad spectrum aminoglycoside resistance was
made. In all clones, with the exception of CC17 that did not contain any, these genes
were present at much higher frequencies than in sporadic isolates, reaching the level of
statistical significance in CC15, CC147 and ST152 (P between 0.0002 and <0.0001).
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Table 29: Frequencies of resistance genes encountered in CRKP

Frequency of resistance genes (%)
Groups

ß-lactamase

n

16S methylases

Any 16S

aac(6')-

TEM

SHV

CTX-M

armA

rmtA

rmtB

rmtC

rmtD

methylase

Ib-cr

All

165

72.1

80.6

80.0

21.2

0.0

1.8

18.8

0.0

40.0

86.7

CC11

20

80.0

60.0

90.0

20.0

0.0

0.0

10.0

0.0

20.0

95.0

CC15

37

64.9

83.8

78.4

37.8

0.0

0.0

5.4

0.0

43.2

97.3

CC17

7

42.9

71.4

42.9

0.0

0.0

0.0

0.0

0.0

0.0

71.4

ST101

5

20.0

80.0

80.0

0.0

0.0

0.0

40.0

0.0

40.0

80.0

CC147

30

70.0

93.3

76.7

46.7

0.0

10.0

6.7

0.0

63.3

86.7

ST152

23

91.3

69.6

91.3

4.3

0.0

0.0

95.7

0.0

95.7

100.0

Sporadic

43

76.7

86.0

79.1

4.7

0.0

0.0

2.3

0.0

7.0

69.8
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4.3 Biocide Susceptibility of K. pneumoniae and E. coli strains

The next part of the project we studied the resistance of carbapenem resistant K.
pneumoniae (CRKP) and E. coli (CREC) isolated from blood to various biocides and
compared them to features of isolates from other sources, as well as to carbapenem
susceptible isolates (CSKP and CSEC) cultured from blood.

4.3.1 The Collection
Strains were collected between 2011 and 2014 from countries of the Arabian
Peninsula. Carbapenem susceptible strains originated from blood, while their resistant
counterparts were from a variety of sources. During analysis the sources, i.e. blood or
non-blood, were taken into consideration. The distribution of the strains is shown in
Table 30.

The strains were subjected to macrorestriction analysis using the stringent
SD>90% similarity threshold to assess any clustering within the carbapenem resistant
and susceptible pools (Figures 20.–23.). As these studies did not reveal any significant
clustering (i.e., the pools were heterogeneous), its potential effect was not considered in
further statistical evaluations.
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Table 30: The source of the isolates

Strain
type
CRKP
CSKP
CREC
CSEC

Source

n

Blood

Sample type

Country of origin

Resp.

Wound

Urine

Screen*

Other

UAE

KW**

KSA

OM***

16

-

-

-

-

-

7

4

3

2

Non-blood

72

23

15

15

14

5

21

10

17

24

Blood

35

-

-

-

-

-

35

0

0

0

Blood

8

-

-

-

-

-

8

0

0

0

Non-blood

35

4

5

14

5

7

21

7

0

7

Blood

25

-

-

-

-

-

25

0

0

0

CRKP – Carbapenem resistant K. pneumoniae
CSKP – Carbapenem susceptible K. pneumoniae
CREC – Carbapenem susceptible E. coli
CSEC– Carbapenem susceptible E. coli
* Screen: Infection control screening samples
**KW: Kuwait
***OM: Oman
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Figure 20: Marcorestriction analysis of carbapenem susceptible E. coli strains
The dashed line represent the threshold of 90% similarity; red boxes identify clusters.

Figure 21: Marcorestriction analysis of carbapenem resistant E. coli strains
The dashed line represent the threshold of 90% similarity; red boxes identify clusters.
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Figure 22: Marcorestriction analysis of carbapenem susceptible K. pneumonaie strains
The dashed line represent the threshold of 90% similarity; red boxes identify clusters.
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Figure 23: Marcorestriction analysis of carbapenem resistant K. pneumonaie strains
The dashed line represent the threshold of 90% similarity; red boxes identify clusters.
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The carbapenem resistant isolates produced a variety of carbapenemases, while 6
of the K. pneumoniae and 12 of the E. coli strains were carbapenemase non-producers
(Table 31.).

Table 31: Distribution of various carbapenemase types among carbapenem resistant
strains
Species

All

K. pneumoniae
E. coli

Type of carbapenemase produced
NDM

OXA

NDM-OXA

VIM

None

88

32

35

10

5

6

43

17

13

0

1

12

In general, comparison between strains of the two species revealed that K.
pneumoniae strains exhibited significantly higher MIC values against benzalkonium
chloride (BENZ) and chlorhexidine (CHEX) (P<0.0001) than E. coli isolates did, while
no significant difference was seen for irgasan (IRG). Similar results were obtained when
comparing the carbapenem resistant subsets of the two species, only (Table 32. and
Table 33.).

4.3.2 Biocide Susceptibility of K. pneumoniae and its Link to Carbapenem
Resistance and Genotype

The susceptibility of the strains to disinfectants, as well as the frequency of genes
potentially associated with biocide resistance is shown in Tables 32. and 33.

Regarding K. pneumoniae strains, bloodstream CRKP isolates exhibited
significantly higher MIC values to chlorhexidine (CHEX) (P=0.0031) than their CSKP
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counterparts, and the difference was also significant when all CRKP strains were
compared to the susceptible ones (P=0.0007). In this later case similar difference was
found for benzalkonium chloride (BENZ), as well (P=0.0031). On the other hand, no
significant differences in susceptibility to any biocides between bloodstream and nonbloodstream CRKP strains were noted (Table 32.).

Three genes, qacδE1, qacE and sugE (P) were present in considerable higher
frequencies in CRKP than in CSKP strains suggesting an association with increased
resistance (Table 33.).

Table 32: MIC values of K. pneumoniae strains against different biocides
CRKP

BENZ

CHEX

IRG

CSKP
All
Non-blood
Blood
88
72
16
35
n
40.36 ± 16.98 40.89 ± 17.79 38.0 ± 12.9
33.83 ± 7.54
x ± SD
32
32
32
32
median
64
64
64
32
MIC90
26.18 ± 11.99 25.67 ± 11.85 28.5 ± 12.72 18.17 ± 10.14
x ± SD
32
32
32
16
median
32
32
32
32
MIC90
7.35 ± 54.83 7.92 ± 60.24 4.75 ± 15.81
1.37 ± 5.42
x ± SD
1
1
0.75
0.5
median
2
1
2
1
MIC90
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan

qacδE1 was significantly associated with CRKP isolates (P=0.0151, Fisher‘s
exact test). The role of qacδE1 in conferring resistance to chlorhexidine (CHEX) was
also highlighted by the fact that the difference between the MIC values against this
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disinfectant among qacδE1 positive versus negative strains (26.52 ± 12.51 vs. 21.86 ±
11.28, respectively) reached the level of significance (P=0.0321). No such difference
was seen regarding the other biocides in this comparison.

MIC values of benzalkonium chloride (BENZ) in strains positive for sugE(P)
(n=10) (51.2 ± 30.91) were significantly (P=0.0133) higher than in the negative isolates
(n=78, 37.87 ± 12.86). However, although sugE(P) positivity was more common among
CRKP strains, this genotype did not show a significant association with this phenotype
(P=0.069). No similar differences regarding other disinfectants were found comparing
these two groups.

Table 33: Frequency of biocide resistance genes in K. pneumoniae
Genes

CRKP

CSKP

All

Non-blood

Blood

n

88

72

16

38

emrE

0.0

0.0

0

2.9

qacδE1

51.1

44.4

81.25

25.7

qacE

4.5

5.6

0

0.0

mdfA

1.1

1.4

0

0.0

ydgE

1.1

1.4

0

0.0

ydgF

1.1

1.4

0

0.0

sugE( c )

1.1

1.4

0

0.0

cepA

97.7

97.2

100

94.3

qacC

0.0

0.0

0

0.0

sugE (P)

11.4

8.3

25

0.0

qacF

0.0

0.0

0

0.0
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As the number of qacE positive strains was too low, i.e. 4 in the CRKP and 0 in
the CSKP group, they were omitted from this analysis.

4.3.3 Biocide Susceptibility of E. coli and its Link to Carbapenem Resistance and
Genotype

For E. coli, as far as MIC values to biocides were concerned, no significant
difference between carbapenem resistant and susceptible blood culture isolates, or in
general, carbapenem resistant and susceptible isolates could be established Table 34.

Table 34: MIC values of E. coli strains against different biocides
CREC

CSEC
All
Non-blood
Blood
43
35
8
25
n
26.23 ± 8.61 25.37 ± 8.99
30.0 ± 5.66
25.6 ± 8.0
x ± SD
BENZ
32
32
32
32
median
32
32
TFC
32
MIC90
1.80 ± 1.21
1.87 ± 1.24
1.5 ± 1.07
1.68 ± 0.99
x ± SD
CHEX
1
1
1
1
median
4
4
TFC
2
MIC90
0.16 ± 0.06
0.16 ± 0.06
0.16 ± 0.06
0.14 ± 0.04
x ± SD
IRG
0.13
0.13
0.125
0.13
median
0.25
0.25
TFC
0.125
MIC90
TFC – Too few to calculate
BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan

The mdfA, ydgE, ydgF, and sugE( C ) genes, while almost completely missing
from the K. pneumoniae isolates, were close to uniformly present in all E. coli strains.
On the other hand, similarly to K. pneumoniae, qacδE1 and sugE(P) were more common
in the carbapenem resistant strains and they both showed a highly significant association
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with the carbapenem resistant phenotype (P=0.0001) (Table 35.). Isolates carrying the
qacδE1 gene exhibited a significantly higher MIC to chlorhexidine (CHEX) (P=0.0329),
but not to the other biocides and, just like in K. pneumoniae, no such correlation was
observed with sugE(P).

Table 35: Frequency of biocide resistance genes in E. coli
Genes

CREC

CSEC

All

Non-blood

Blood

n

43

35

8

25

emrE

67.4

68.6

62.5

52.0

qacδE1

76.7

80.0

62.5

28.0

qacE

2.3

0.0

12.5

0.0

mdfA

97.7

97.1

100.0

100.0

ydgE

97.7

100.0

87.5

96.0

ydgF

97.7

100.0

87.5

96.0

sugE(c)

95.3

97.1

87.5

100.0

cepA

0.0

0.0

0.0

0.0

qacC

0.0

0.0

0.0

0.0

sugE (P)

39.5

42.9

25.0

0.0

qacF

7.0

5.7

12.5

4.0

In E. coli, emrE occurred more commonly in carbapenem resistant strains, but
this association did not reach the level of statistical significance and the MIC values of
strains positive for this gene did not exhibit significantly higher MICs to any of the
disinfectants.
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4.3.4 Biocide Susceptibility in Relation to the Carbapenemases Produced

The relationship between susceptibility to disinfectants and the type of
carbapenemase produced by carbapenem resistant strains was also investigated. The
results are summarized in Tables 36. and 37.

Table 36: MIC of biocides against K. pneumoniae strains producing different
carbapenemases
MIC (mg/L)
CPase

NDM

OXA

NDM-OXA

VIM

None

n

32

35

10

5

6

BENZ

38.0 ± 12.69

40.69 ± 15.2

40.00 ± 17.28

64.0 ± 39.19

32.0 ± 0.0

CHEX

27.25 ± 13.15

24.69 ± 11.04

25.6 ± 8.26

32.0 ± 19.6

25.33 ± 10.63

IRG

0.88 ± 0.52

0.8 ± 0.41

58.3 ± 160.63

0.7 ± 0.27

0.58 ± 0.34

BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan

Table 37: MIC of biocides against E. coli strains producing different carbapenemases
MIC (mg/L)
CPase

NDM

OXA

NDM-OXA

VIM

None

n

17

13

0

1

12

BENZ

27.29 ± 7.51

28.31 ± 7.02

NA

NA

22.0 ± 10.85

CHEX

1.71 ± 0.99

1.69 ± 1.32

NA

NA

2.13 ± 1.45

IRG

0.17 ± .06

0.16 ± 0.06

NA

NA

0.15 ± 0.05

NA – Not applicable

BENZ-Benzalkonium Chloride, CHEX- Chlorhexidine, IRG- Irgasan
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Statistical analysis of the different carbapenemase producing groups with at least
10 members revealed no significant difference between them regarding the MIC values
of different biocides in E. coli. In K. pneumoniae, applying the same criteria, irgasan had
significantly higher MIC to NDM-OXA producing strains that to those producing these
two enzymes alone (P=0.0439 and 0.0345, respectively).
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4.4 Fosfomycin Susceptibility of K. pneumoniae Strains

Since intravenous fosfomycin is currently not available in the UAE, routine
testing of susceptibility to this drug is not carried out for Enterobacteriaceae causing
infections beyond the urinary tract. Consequently, local resistance data for K.
pneumoniae isolates are not available. As previously our laboratory studied the
fosfomycin resistance rate of E. coli strains (Amna Baloushi, PhD thesis, manuscript in
preparation) we extended these investigations to K. pneumoniae. During these studies
the same group of CRKP and CSKP strains were used as for the investigations on
susceptibilities to disinfectants (see 4.3 in this Thesis). The cluster structure of the pools
of strains are provided there.

Using the MIC≤32 mg/L EUCAST clinical breakpoint of fosfomycin the
resistance rate we found were different in the CRKP and CSKP collections; 69 of the 88
CRKP (78.4%) and 32 of the 35 CSKP (91.2%) showed susceptibility to this antibiotic.
However, this difference was not statistically significant (Fischer‘s exact test;
P=0.1822). If we compared the different subgroups of CRKP, i.e. isolates from sources
other than blood, blood isolates and urine isolates, we found that blood CRKP isolates
were significantly more likely to be resistant to fosfomycin than non-blood (P=0.0002)
or urine (P=0.0059) CRKP isolates, whereas the resistance rate was similar in non-blood
CRKP (11%) and CSKP (8.5%) isolates. If the blood isolates were compared to each
other, i.e., CRKP blood vs. CSKP, carbapenem resistance was significantly associated
with fosfomycin resistance (P=0.0005). The MIC50 and MIC90 values of the respective
strain collections are shown in Table 38.
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Table 38: Fosfomycin, colistin and tigecycline MIC of K. pneumoniae strains

CRKP
Mg/L
FOS
COL
TGC

All
Non-blood
Blood
Urine
88
72
16
15
n
16
8
64
8
MIC50
64
64
256
32
MIC90
0.5
0.5
0.5
0.5
MIC50
4
4
64
32
MIC90
1
1
1
1
MIC50
8
8
2
8
MIC90
FOS-Fosfomycin, COL- Colistin, TGC- Tigecycline

CSKP
35
8
16
0.25
0.5
0.5
1

It is noteworthy that while over 90% of the CSKP isolates were susceptible to the
three antibiotics tested, the MIC90 value of the CRKP collection to all three
antimicrobials was higher than the clinical breakpoint of these antibiotics, respectively.

Since fosfomycin therapy is considered as an alternative in case of CRKP
infection, but not recommended as monotherapy in case of a non-urinary tract infection,
we assessed the association in the CRKP collection between resistance to fosfomycin
and resistance to antimicrobials, which may be used in combination, i.e. colistin or
tigecycline. It was found that resistance to neither of these antibiotics is associated with
fosfomycin resistance (fosfomycin vs. colistin P=0.0963 and fosfomycin vs. tigecycline
P=0.42, respectively). However, when evaluating the association in blood isolates
(CSKP and CRKP together) between the resistance to the two antibiotics, which could
be used in bloodstream infections, i.e. fosfomycin and colistin, a significant association
was found (P=0.0106).
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As the majority of clinically relevant fosfomycin resistance observed nowadays
is due to the fosfomycin inactivating resistance genes (fosA-type or fosC genes) we
tested the presence of these in our collection by PCR. We found that while none of the
strains were positive for fosC, more than ¾ of both CRKP and CSKP collection
harbored the fosA gene (78.4% and 77.1%, respectively). However, the presence of the
gene did not show any association with the phenotypic fosfomycin resistance. Sequence
of the fosA PCR products of two fosfomyin resistant (ABC189 MIC>1024 mg/L and
KW11 MIC=128 mg/L) and one fosfomycin susceptible strain (ABC52 MIC=4 mg/L)
revealed 99-100% identity with fosA genes of 43 K. pneumoniae whole genomes
deposited in the GenBank. A comparison of partial fosA of the above three strains and a
plasmid-borne fosA gene of E. coli HKU1 (KC960485) and a chromosomally located
fosA of K. pneumoniae 30660/NJST258 (CP006923) is shown, as a screenshot, on
Figure 24.
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Figure 24: Alignment of partial fosA genes of KC960485 and CP006923 (GenBank) to
sequenced fosA PCR products of K. pneumoniae strains ABC52, KW11 and ABC189

These findings suggest that fosA may be present on the chromosome of a
majority of K. pneumoniae, but not always expressed. Study of the possible expression
differences of fosA gene was beyond the scope of our project. However, we tested
whether the fosA gene was plasmid-borne in the strains showing phenotypic fosfomycin
resistance by Southern blotting of plasmid gels and hybridizing the positively charged
nylon membranes with digoxigenin labeled fosA probe.

We did not observe any hybridization signal on the membrane (data not shown). To
further prove that the fosfomycin resistance determinant was not transferable, we
attempted to conjugate the resistance feature from K. pneumoniae ABC189, which
exhibited the highest MIC to fosfomycin in the collection (MIC>1024 mg/L), with E.
coli J53RAZ at 30oC and at 37oC. We also isolate plasmid DNA from the same K.
pneumoniae isolate and transformed it in E. coli DH5α. None of these experiments
resulted in fosfomycin resistant E. coli derivatives.
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Chapter 5: Discussion
An important feature of the recent epidemiology of infections due to members of
the Enterobacteriaceae family, particularly E. coli and K. pneumoniae strains, is that a
considerable part of the cases are attributed to particular clones, i.e., strains closely
related to each other implying that they stem from common ancestors. As clinically one
of the most relevant feature of these strains is their often increased antibiotic resistance,
and as they are disseminated globally, they are commonly referred to as multi-drug
resistant, MDR pandemic clones (Pitout, 2012).

Although their epidemiology has been extensively studied, we still do not
understand what makes certain strains capable of expanding and spreading while others
are confined to sporadic infections, only. As we believe that a better understanding of
the basis of their propagation and spread would help to mount a better control system
against them, we studied such isolates recovered in the Arabian Peninsula using a
variety of genotyping and fingerprinting methods and phenotypic assays. These studies
were not only meant to address the above global questions, but also to characterize such
local strains, i.e., a field having been considerably neglected, so far.

Blood-stream infections are the most serious ones among extraintestinal E. coli
(ExPEC) infections. The characterization of the 172 local blood-stream isolates mostly
yielded the expected results, at least initially. The most common phylogenetic type was
B2 followed by D (Dale and Woodford, 2015; Riley, 2014). Also, the strains exhibited a
relatively high rate of resistance to a variety of antibiotics and the over 30% of the
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strains produced ESBL, mostly of the CTX-M-15 type. The spectrum of virulence factor
genes encountered was also in line with anticipation: a high frequency of presence of
pathogenicity island (PAI), secreted autotransporter cytopathic toxin sat, the C5b6
complex inhibiting, serum resistance associated traT, the type 1 fimbria gene fimH,
group II capsule gene KpsMTII, yersiniabactin fyuA and iron uptake gene iut were all
anticipated to be common among extraintestinal isolates and have been broadly
documented earlier (Dale and Woodford, 2015; Johnson et al., 2009; Pitout, 2012; Riley,
2014).

On the other hand, PCRs targeting various core biosynthesis genes yielded, at
least partly, unexpected results. Based on previous reports (Amor et al., 2000;
Appelmelk et al., 1994; Gibb et al., 1992; Gibbs et al., 2004), one could have anticipated
an overpowering dominance of strains with an R1 core type (Table 39.). The high rate of
the previously rare K-12 core type was to some extent already anticipated as we have
previously shown that members of the global ST131 clone carries this core type (Szijártó
et al., 2012). However, the comparatively high rate of the R4 core type was considerably
different from previous observations.

The fact that the overwhelming majority (86.7%) of R4 core type strains
belonged to phylogenetic group D lead us to the assumption that clustering of strains
into clones could be responsible for the phenomenon. MLST studies confirmed this
hypothesis and we identified three, well known international clones (ST38, ST405 and
ST648) present among local isolates with a group D phylogeny and R4 core. Actually,
all major STs identified in the current study consisted of strains expressing a previously
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rare core type: the ST131 the K-12 type, as described earlier, the ST38, ST405 and
ST648 strains the R4 core type.

Table 39: Comparison of core type distribution found in this study to previous
observations
Core type (%)
Sample

R1

R2

R3

R4

K-12

Blood
Urine
Feces

61
81
52

7
5
19

15
5
10

-

-

NonR1-3
16
10
19

Blood

68

6.5

8.7

5.1

3.2

-

*ECOR
Feces
(human)
Feces
(cattle)

69.4

11.1

11.1

2.8

5.6

-

63

15

4

14

4

-

49

11

11

25

4

-

All Blood
Main ST**
Others

33.72
0
52.25

8.14
0
12.61

18.02
0
27.93

17.44
39.34
5.41

22.67
60.66
1.80

-

Reference

(Gibb et al., 1992)
(Appelmelk et al.,
1994)
(Amor et al., 2000)
(Gibbs et al., 2004)

This study

* ECOR: A reference collection of E. coli strains found in nature
**ST38, ST131, ST405 and ST648 combined

These STs have all been recognized to cause extraintestinal infections around the
globe. Often they are known to produce, just as observed in the current study, various
alleles of CTX-M type ESBLs (Pitout, 2012).

The best documented global outbreak is clearly caused by ST131 strains (Peirano
and Pitout, 2010). However, CTX-M-9,-14, and -15-producing ST38 strains have been
reported form Japan (Suzuki et al., 2009), from the Netherlands (van der Bij et al.,
2011), from Korea (Kim et al., 2011), and from Tanzania (Mshana et al., 2011). Strains
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associated with OXA and NDM type carbapenemase production have also been
described (Poirel et al., 2011a.; Yamamoto et al., 2011). CTX-M producing ST405 and
ST648 have also been observed globally (Coque et al., 2008; Jones et al., 2008; Mihaila
et al., 2010; Smet et al., 2010; van der Bij et al., 2011; Zong and Yu, 2010) and their
carbapenemase producing varieties have also been documented (Hornsey et al., 2011;
Mushtaq et al., 2011).

The clones we encountered in the current study differed from each other
substantially. On the one, hand all clones were resistant to a broader spectrum of
antibiotics than isolates not clustered into clones (Table 17.). However, with the
exception of ST131, they were less virulent than strains not belonging to any of the
clones, as substantiated by their lower virulence score (Table 17.). Actually, ST131
strains are known to be uniquely virulent compared to other ExPEC isolates (Johnson et
al., 2009; Pitout, 2012).

As far as resistance to antibiotics is concerned, while the clones we encountered
locally were definitely more resistant that sporadic isolates, it is not clear if this is the
reason or the consequence of their emergence. Theoretically it would be logical to
assume that strains with more resistance have better survival chance in antibiotic-soaked
environments. However, on the other hand susceptible, highly successful clones, such as
ST95 and ST393 are known (Riley, 2014). Furthermore, the fact that some of these
clones are also more common in community acquired cases (i.e., environments still less
challenged by antibiotics that in hospital settings) argues against this reasoning (Riley,
2014). Alternatively, one may assume that as fit clones expand, they are increasingly
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exposed and hence become more resistant. Currently, based on the data in the literature
and our own observations, we cannot exclude either scenarios.

We believe that our finding, i.e., that in addition to the K-12 core of ST131
strains previously described (Szijártó et al., 2012) three further clones express a
previously relatively rare core type, i.e. R4, is worth further attention.

One may

speculate that the previously low rate of K-12 and relatively low rate of R4 core type
strains could leave the population less exposed to, and hence less primed by this
antigens. In fact, a relation between the frequencies of various core types encountered
and the level of specific antibodies found has been documented (Gibbs et al., 2004).
Theoretically, this could lead to a naïve population with increased susceptibility to
strains expressing these antigens.

The obvious question is whether immune mechanisms specific to core antigens
could lower the chance of infection or colonization with strains expressing them? It
should be kept in mind, that the presence of serum, or even that of mucosal antibodies
does not have a protective effect per se particularly, if the antigen targeted is such a
relatively hidden antigen, as the core epitopes are. This is one of the main reasons why
the possible role of core, as a potentially ―protective antigen‖ is not without
controversies.

But being located ―deep‖ in the cell wall may not completely eliminate the
possibility that these antigens are targeted by immune mechanisms. Our earlier studies
with rough shigella vaccines (Szijártó et al., 2013) have shown that epitopes located
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deep in smooth strains are accessible to immune mechanisms to the extent that immune
response targeting them can result in protection in in vivo models (Szijártó et al., 2013).
One of the most likely protective epitopes were those located in the core.

Some studies failed to show a protective effect of core specific antibodies (Russo
et al., 2009; Van Dijk et al., 1981), while others argue the opposite (Cross et al., 2004;
Di Padova et al., 1993; Müller-Loennies et al., 2007), although it should be noted that in
some of these studies neither the epitope nor the mode of action were clearly defined,
and in some cases, it was likely the anti-endotoxin, instead of the anti-bacterial effect
which was evaluated. Nevertheless, in line with our own suggestion, it is noteworthy
that based on their sero-epidemiological studies, Currie et al postulated that the anti-R3
core mucosal immune response could play a role in preventing either the infection or the
colonization by E. coli O157 strains (Currie et al., 2001).

In conclusion, with the understanding that the majority of extraintestinal
infections are due to strains previously permanently or temporarily colonizing the gut,
based on our findings regarding the dominance of K-12 and R4 core type, we propose as
a hypothesis for further studies, that the relative naivety of the population towards K-12
and R4 core antigens could have contributed to the emergence of these clones by making
easier for these strains to colonize the gut and hence, eventually cause infections. It is
clear to us that proving this hypothesis needs further studies, which would reveal
whether other clones spreading globally also carry some of the previously rare core
types. Also, their frequencies in the gut flora of healthy carriers should be studied and
finally, their increased colonizing potentials, if present, should be assessed in
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experimentally challenged immune and non-immune hosts. These are the questions, as
outcomes of this project, our laboratory is planning to address in the future.

Next we characterized carbapenem resistant K. pneumoniae strains encountered
in the Arabian Gulf countries. In the past few years, this group of pathogens have
endemic in the region (Zowawi et al., 2014) with high incidence rates of (approximately
6% of K. pneumoniae strains in Abu Dhabi – Dr. Jens Thomsen, Health Authority Abu
Dhabi, personal communication) and mortality and, as our laboratory showed it recently,
with extensive autochthonous transmission (Sonnevend et al., 2015b).

With regards of study of 165 CRKP strains, the first important observation was
that 26.1% of them could not be linked to clusters forming known STs or CCs (Table
18.). Members of CCs and STs encountered locally have been well known for their
outbreak potential (Arena et al., 2013; Baraniak et al., 2015; Del Franco et al., 2015;
Hasan et al., 2014; Nagasaka et al., 2015; Park et al., 2015). However, beyond
describing STs 14, 147 and 152 in the Arabian Peninsula (Sonnevend et al., 2015b), very
little has been known earlier about the characteristics of locally spreading lineages.
Furthermore, the local detection of CC11, CC17, ST 101 are new observations. These
clones were not evenly distributed among the countries (Table 20.) although the large
were represented in multiple countries. This indicates their cross-border spreading
potential with the implication that proper tracing the routes of their dissemination, and to
interfere with it, is unlikely to succeed without international cooperation. One exception
from this pattern was an outbreak of ST152 present exclusively in Riyadh, KSA,
affecting multiple hospitals.
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A noteworthy observation is the higher rate of NDM producers and the lower
rate of carbapenemase non-producers among clonal strains compared to non-clonal,
sporadic isolates (Table 22.). Theoretically, such distribution could imply the possibility
that expressing certain type of carbapenemase would automatically provide
epidemiological advantage to these strains. We would like to disagree with such
arguments. Outbreaks with strains producing OXA-48-like carbapenemases are known
to occur (Poirel et al., 2012) and clustered occurrence of such strains have even been
reported even from the Middle East before (Zowawi et al., 2014). Even in the current
collection, one of the clones (CC17) were dominated by OXA-producing isolates (Table
22.). Furthermore, with the notable exception of the highly homogenous ST152 clone
producing almost exclusively NDM, our results have shown that most clones, sometimes
even PFGE clusters within clones, can produce different carbapenemases (Figures 13.18.). This can easily be attributed to the known plasmid coded nature of the majority of
carbapsenemases (Mathers et al., 2015).

One may argue, that MBL enzymes, such is NDM, unlike OXA-type enzymes,
are also hydrolyzing broadly used cephalosporins (El Salabi et al., 2013) and this could
provide an advantage for NDM-positive isolates. However, its effect could be rather
limited as over 80% of the isolates also expressed some kind of ESBL enzymes causing
resistance to 3rd and 4th generation cephalosporins on their own (Table 29.). We believe
that the explanation for NDM being more associated with the clones in this study could
be the geographical location of the current investigation: despite the role of
autochthonous acquisition of a considerable number of CRE infections, the area could
still have closer epidemiological connection to the Indian Subcontinent dominated by
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NDM producers rather than to the Mediterranean region more characterized by OXA
positive isolates (Sonnevend et al., 2015b). In fact, in this study, it was observed that
cases linked to previous foreign hospitalization, mostly in India, were almost exclusively
due to NDM producing isolates. However, only further, more detailed epidemiological
studies could validate this speculation.

The limited outbreak potential of carbapenem resistant, but carbapenemase nonproducing strains have been known (Drew et al., 2013). In the fact that these isolates
were more common among those not clustered into clones was not surprising.

When investigating the virulence-related features of the clones, a picture rather
similar to that observed with E. coli blood-stream isolates emerged. The general
frequencies of the virulence genes (Table 24.) were similar to those found in previous
studies (Candan and Aksöz, 2014; El Fertas-Aissani et al., 2013), the most commonly
encountered ones being fimbrial adhesins (mrkD, fimA), cell wall synthesis genes (ugeA
and wabG) and those related to iron acquisition (fyuA). Importantly, no noticeable
difference were noted between clonal and sporadic isolates.

On the other hand, some considerable differences in the distribution of virulence
factors were noticed between clones, a variability noticed earlier as well (Lascols et al.,
2012). In this study certain clones, as assessed by their by virulence-score, were found to
be more virulent than other ones or sporadic strains (e.g. members of CC15), while
others scored lower (e.g. CC147). It was noteworthy that the highly virulent CC15
strains had the highest carriage rate of iron-uptake related kfuBC while it was almost
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completely missing from low-virulence type CC147. The same applied to heat tolerance
associated clpK gene (Bojer et al., 2010). However, while these genes were the most
common in the most, and least common in the least virulent clones, they were also
encountered among sporadic isolates, and some where even completely missing from
some clones (Table 24.). Consequently, their mere presence or absence is unlikely to be
the single reason of clonal spread.

Similarly varying results were obtained when investigating serums resistance and
biofilm forming capacity. On one hand clones considerably varied in these features and
did not differ in these respects from sporadic isolates to the extent that these features
could account for the epidemiological fitness (Table 25.). Even though there were more
members of the clones scored as ―strong biofilm producer‖ than encountered among
sporadic isolates, this feature was also present in the latter group in nearly 75% of the
strains, and if strong and moderate biofilm producers were counted together, sporadic
isolates were not inferior (Table 25.).

Clones were not homogenous regarding the biofilm producing capacities of their
members. However, studying to what intra-clonal differences these phenomenon was
due to went beyond the scope of the current study.

Recently, a hypervirulent variety of K. pneumoniae associated with the highly
mucoid phenotype emerged (Shon and Russo, 2012). It was noteworthy that only 5
strains in our entire collection exhibited this feature showing no association with any of
the clones. This is was supported by the fact that the K1 or K2 associated genes, magA
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and rmpA (Yeh et al., 2007) were rarely encountered among the isolates (Table 24.). On
one hand it shows that this type is still rather rare in the region and on the other it
suggest that this cannot be considered as a feature providing epidemiological fitness.

In general, the strains studied were highly resistant to multiple antibiotics (Table
27.). One should keep in mind, that the pool studied was a highly selected collection, i.e.
the inclusion criteria was ―non-susceptibility to carbapenems‖. This could explain their
uniformly high resistance rate to all ß-lactams (Table 27.). As we did not have group A
carbapenemase (e.g. KPC) producing strains in our collection, and as MBLs and group
D enzymes, i.e., NDM and OXA-type enzymes, are inactive against it (Tzouvelekis et
al., 2012), the high rate of resistance to aztreonam found across the entire collection
suggests the wide-spread presence of ESBLs which was confirmed by the common
presence of TEM, SHV and CTX-M specific genes (Table 29.).

Unlike the above uniformity, a notable difference between groups regarding
resistance to non-ß-lactam antibiotics was observed. With the exception of the small
clone CC17, all clones were more resistant to these heterogeneous group of agents, than
sporadic isolates (Table 28.). These strains carried somewhat more frequently the
fluoroquinolone modifying gene aac(6')-Ib-cr than their non-clonal counterparts (Table
29.). This, however, in itself is unlikely to provide an explanation for the less explosive
spread of sporadic isolates. This is just one possible mechanism of resistance to these
drugs beyond target alteration and target shielding (Redgrave et al., 2014) and the gene
was present, although less frequently, but still by almost 70% in the sporadic isolates, as
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well. Indeed, more than 3 quarter of the sporadic strains were also resistant to
ciprofloxacin (Table 27.).

The most striking difference between clonal and non-clonal isolates was
encountered in the aminoglycoside class. Clonal groups, except CC17, were highly
resistant to gentamicin, and to a considerable extent to amikacin, as well, while much
lower resistance rates were observed in the non-clonal group (Table 27.). This correlated
well with the wide-spread presence of various, mostly armA and rmtC type 16S
ribosomal subunit modifying enzymes (Table 29.). Several mechanisms exist conferring
resistance to aminoglycosides by producing enzymes with relatively narrow spectrum,
i.e., being active against one or a few aminoglyocosides, only (Ramirez and Tolmasky,
2010). However, target modifying 16S ribosomal methylases, often coded by mobile
elements, confer resistance to a broader spectrum of aminoglycosides (Wachino and
Arakawa, 2012). The fact that with the exception of the small CC17 clone, at least some
members of all clones (varying between 21.0 and 95.7%) carried at least one of those
genes suggests a close association with clonal spread as these genes were present in
only 7% among sporadic isolates (Table 29.).

Aminoglycosides are commonly used, usually in combination with other drugs to
treat infections caused by carbapenem resistant strains (Morrill et al., 2015). Hence,
resistance could certainly provide a considerable advantage to spread in hospitals. It
should also be kept in mind, however, that representatives of the group are also
commonly applied in severe infections due to strains not (yet) resistant to carbapenems
(Leibovici et al., 2009).
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As mentioned earlier, relatively susceptible E. coli clones spreading globally are
known (Riley, 2014). In the current study we did not encounter such CRKP clones, as
the selection criteria, i.e. non-susceptibility to carbapenems does obviously strongly
favor the MDR phenotype. Even the small CC17 clone lacking any 16S methylase genes
was more resistant to amikacin and tobramycin then sporadic isolates, probably due to
various aminoglycoside modifying enzymes. The detection of those was beyond the
scope of the project.

Although the current study has not addressed the determination of the possible
sequence of events, i.e. resistance to aminoglycosides first followed by resistance to
carbapenems or vice versa, the fact the carbapenems are usually used when ―more
common drugs had failed‖ supports the first scenario. Obviously, a strain, even a
relatively susceptible one, could easily acquire a plasmid coding for a carbapenemase in
the gut of a patient, even if the patient is not under any therapy. However, if the strain is
resistant to a broader panel of drugs (among others to aminoglycoside) it could have a
better chance to spread, i.e. develop into a wide-spread clone, once exposed to different
antibiotics. In that sense, resistance to a broader spectrum of non-ß-lactam drugs could
facilitate to become clonally wide-spread.

The rates of resistance to colistin and tigecycline should be mentioned separately
as these are drugs used almost exclusively to treat CRKP and not CSKP infections and
for colistin, until very recently (Liu et al., 2015) resistance was considered
chromosomally located, not transferable. With considerable variation between clones
some had clearly higher resistance rate to these drugs than sporadic isolates (Table 27.).
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We surmise, however, that the still relatively low rate of these resistance to these drugs
(however alarming their increase and their effect on the outcome of the specific cases
could be), argues that these phenotypes are not factors determining whether out of a
particular strain a globally spreading clone develops or not.

Taken together, analyzing CRKP isolates, our conclusion is similar to the one we
reached regarding E. coli: no specific virulence traits seem to be associated with the
clonal nature, and there are apparently successful clones with rather low virulence
scores. The resistance to a broader range of drugs are more associated with clonal
isolates, and in case of CRKP, we believe that this is particularly clear regarding
aminoglycoside drugs. As with E. coli, however, the chance that this is a consequence
rather than the reason of becoming clonal, can only be established by investigations
studying outbreaks due to susceptible clones.

While all hospital laboratories regularly monitor resistance to antibiotics, such
studies for disinfectants are not part of the routine. However, emerging resistance to
these agents may have direct impact on the spread of pathogens. This is certainly true for
microbes known to colonize surfaces and often causing exogenous infections (e.g.
MRSA), but could equally be true for agents primarily causing endogenous infections,
such as Enterobacteriaceae. While, to a large extent, gut colonizer MDROs spread by
food (Riley, 2014), the role of direct or indirect contacts in their transmission, both to be
controlled by the application of disinfectants, should not be underestimated. Therefore,
we studied the biocide resistance of carbapenem resistant E. coli and K. pneumoniae and
compared it to the figures seen in their carbapenem susceptible counterparts. It should be
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noted that the only differentiating marker between these groups was the susceptibility to
carbapenems, i.e. some of the members of the latter groups also qualified as MDR,
although susceptible to carbapenems.

Regarding E. coli, we found no significant difference in biocide susceptibility
between the CREC and CSEC groups and a very similar distribution of disinfectant
resistance genes than others (Guo et al., 2015; Zou et al., 2014) with chromosomally
encoded emr, ydgA, ydgF, mdfA, sugE(C) being the most common ones (Table 35.).
Importantly, another study has also failed to detect significant differences between MDR
and susceptible groups (Guo et al., 2015) although in that project susceptibility to
carbapenems were not analyzed. It should be noted that similarly to others (Zou et al.,
2014) we also detected a higher rate of presence of the plasmid coded qacΔE1 and
sugE(P) genes (Kücken et al., 2000) among the more resistant isolates (Table 35.).
Although carriers of the former gene exhibited a significantly higher MIC values to
chlorhexidine than their negative counterparts, apparently the presence of the gene in the
CREC group was still not widespread enough to cause significant difference in
resistance compared to CSEC strains. Nevertheless, even though the absolute figures of
MIC values are not high among local E. coli, the presence of plasmid-coded disinfectant
resistance genes, and their future spread needs further monitoring.

A considerably different picture emerged regarding K. pneumoniae strains. On
one hand, the absolute MIC values of chlorhexidine and benzalkonium for this species
were significantly higher than for E. coli (Tables 32. and 34.). Unlike in E. coli, a highly
significant difference existed between CRKP and CSKP isolates regarding chlorhexidine
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and benzalkonium susceptibility. Most of our isolates contained the cation efflux gene
cepA, and we could not correlate its presence with resistance to disinfectants. This gene
was described to be present in all strains of a collection of pre-antibiotic era K.
pneumoniae strains but in those with lower MIC values the gene was disrupted by a 9-18
bp insert (Wand et al., 2015). Confirming the same reason in our collection was beyond
the scope of the study.

Similarly to E. coli, plasmid-coded qacΔE1 and sugE(P) (and in small numbers,
i.e. 4 strains, qacE) were more commonly present in CRKP then in CSKP isolates, and
in case of qacΔE1 it even reached the level of statistical significance. We believe that
this observation is of particular importance. In enteric bacteria qacΔE1 is commonly
located at the 3‘ conserved part of class 1 integrons, a structure frequently present in
various resistance plasmids (Deng et al., 2015). They are also observed in plasmids
carrying different carbapenemase genes (Zhao and Hu, 2015). In the current study we
could not find any association between disinfectant resistance and any particular
carbapenemase produced and the detailed molecular structure of the NDM and OXA
plasmids were not established. Nevertheless, one can easily predict that the spread of
carbapenem or other antibiotic resistance plasmids selected for by the existing antibiotic
pressure, but also harboring these biocide resistance genes could seriously impact the
general level of disinfectant resistance in our hospitals. Its effect will just be further
augmented by the impact of broad substrate range efflux pumps selected for by
antibiotics but affecting disinfectants simultaneously (Tumah, 2009).
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One should keep in mind that there are no ―clinical breakpoint‖ values
established for disinfectants to distinguish between susceptible and resistant isolates.
While it has been shown that these agents are very effective against Gram-negative
MDR organism (Reichel et al., 2014) it is still debated whether decreased susceptibility
to these agents has any impact on health care (Harbarth et al., 2014). We believe that
while these agents are applied in concentration way exceeding their MIC values,
concentrations do decrease in distance and particularly in time after their application.
Unless used with strict regularity, their subsiding concentration will allow organisms to
grow, particularly those with higher MICs. Therefore a continuous monitoring of the
level of resistance to these agents, particularly among high impact pathogens, such as
CRKP and CREC, is fundamental to maintain safety of health care.

Fosfomycin, a bactericidal antibiotic, was discovered in 1969 in Spain, and
found to be active against a wide range of pathogens, including multi- or even
extensively drug resistant Enterobacteriaceae (Endimiani et al., 2010). It is assumed
that the unique mechanism of action of this drug, i.e., the inactivation of pyruvyl
transferase required in the early stage of cell wall peptidoglycan synthesis, prevents
cross resistance with other classes of antibiotics (Popovic et al., 2010). Fosfomycin is
considered to be one of the few ―last resort‖ antibiotics in case of infections caused by
carbapenem resistant Enterobacteriaceae, but its use in enterobacterial infections other
than the ones in the urinary tract caused by Escherichia coli is not standardized, and the
recommended intravenous formulation, fosfomycin disodium, is not universally
available (Popovic et al., 2010). Furthermore, clinical breakpoints for fosfomycin iv. for
non-urinary

tract

infections

are

only

set

by

EUCAST
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(www.eucast.org/clinical_breakpoints/). Hence, we used the EUCAST breakpoints when
evaluating the MIC values into susceptible, intermediate and resistant categories. Our
investigation showed that although somewhat lower percent of CRKP collection was
susceptible to fosfomycin, this was not significantly different from the value of the
CSKP isolates, demonstrating that fosfomycin is a possible therapeutic option against
CRKP in countries of the Arabian Peninsula. In recent studies, susceptibility to
fosfomycin of carbapenemase producing K. pneumoniae has been reported to be 93%
(Endimiani et al., 2010) and 86% (Alexander et al., 2012) in the USA, 94.8% in Greece
(Falagas et al., 2010) and 78.5% in Madrid, Spain (Pena et al., 2014). However, with the
exception of the latter study, the higher clinical breakpoint values set by the CLSI for
urinary tract E. coli isolates only (CLSI, 2014) were used, although, Endimiani et al.
reported that if the MIC≤32 mg/L clinical breakpoint was used, 75% of their KPCproducing K. pneumoniae would have been classified as susceptible, only.

Our CRKP collection exhibited 78.4% susceptibility to fosfomycin, which is in
line with observation in the US and Spain. It is noteworthy, that the CRKP fosfomycin
resistance rate is similar in regions where the use of fosfomycin is generally lower, i.e.,
the US and countries of the Arabian Peninsula, compared to Spain or Greece, where
intravenous fosfomycin is available and the selective pressure is supposedly higher. A
possible explanation may arise from our search for transferable fosfomycin resistance
genes, which also brought unexpected results. We could not identify plasmid mediated
fosA or fosC genes. However, the fosA PCR was positive in approx. 3/4 of our
collections of CSKP and of CRKP, both of which were non-clonal, but pools of diverse
strains as shown by their PFGE profiles (Figure 22. and 23.). This finding is further
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supported by the fact that we could identify a fosA-like gene in silico in a large
proportion of K. pneumoniae whole genomes deposited in the GenBank. We speculate
that the expression of this gene, and subsequently the level of fosfomycin resistance may
vary in different K. pneumoniae strains. It is also possible that the chromosomally
located fosA gene may act as a source of such genes, and when they are mobilized into
plasmids, this may elevate the fosfomycin MIC into a clinically resistant range (Lee et
al., 2012; Li et al., 2015; Qin et al., 2014). However, addressing these hypotheses is
beyond the scope of this dissertation, and it is part of further ongoing studies.

It has been observed in vitro that fosfomycin resistance may develop rapidly in a
bacterial population, hence it is recommended to use it in combination with other drugs
(Lee, 2014). The drugs that have been shown to be synergistic with fosfomycin are
carbapenems, colistin, netilmicin and tigecycline in vitro (Samonis et al., 2012).
Therefore, in order to avoid resistance emerging during therapy, intravenous fosfomycin
therapy of CRKP is usually combined with aminoglycosides, colistin or tigecyline (Lee,
2014; Pontikis et al., 2014; Tängdén and Giske, 2015). We focused on the latter two
drugs, since our collection of CRKP mostly consisted of NDM and OXA-48-like
carbapenemase producing K. pneumoniae (Table 31.), and aminoglycosides were
described to be useful in the treatment of KPC-producer CRKP strains, only (Endimiani
et al., 2010; Lee, 2014; Pontikis et al., 2014).

We also evaluated the MIC of the above bacterial isolates for colistin and
tigecycline based on the EUCAST criteria, as the CLSI has no standard for these
antibiotics (CLSI, 2014; EUCAST, 2013). Although the rate of susceptibility to
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tigecycline and colistin in the CRKP collection was 78.4% and 88.6%, values similar to
those seen for fosfomycin, we found no significant association between the resistance to
these three antibiotics, predicting the effectiveness of fosfomycin in case of CRKP
isolate resistant to tigecycline or colistin. This may be promising, but in a prospective
study using fosfomycin combination treatment in extensively drug resistant
carbapenemase-producing Klebsiella pneumoniae infections of critically ill patients, the
best clinical and microbiological outcome was found in bloodstream infections (Pontikis
et al., 2014), and unfortunately, the blood isolates of our CRKP collection exhibited the
highest fosfomycin MIC values (Table 38.). Furthermore, in this subgroup of our CRKP
isolates the fosfomycin resistance was significantly associated with colistin resistance,
leaving virtually no effective antibiotic treatment option. On the other hand, our finding
showed that more than 90% of our CRKP urine isolates were susceptible to fosfomycin,
with MIC50 and MIC90 being 8 mg/L and 32 mg/L, respectively, values comparable to
the CSKP collection‘s MIC50 and MIC90. These promising results regarding urinary
tract infections caused by CRKP, however, should also be treated with caution, since in
one of the few studies evaluating the clinical use of fosfomycin in UTI caused by CRKP,
the microbiological cure rate was only half of the in vitro susceptibility to this drug: 46%
vs 92% (Neuner et al., 2012).

Considering our findings and previous observations, fosfomycin could be a
useful addition to the treatment of extremely drug resistant CRKP in the Arabian
Peninsula, especially in non-bloodstream infections. Nevertheless, further data regarding
combination therapy and patient related factors should be evaluated before a
recommendation on fosfomycin use in CRKP infections could be formulated.
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Chapter 6: Conclusion & Recommendations


In this study, we have identified several internationally recognized E. coli and K.
pneumoniae pandemic clones causing infections and outbreaks in hospitals of the
Arabian Peninsula. Provide their first thorough characterization. Their presence
and local spread calls for the establishment of state-of-art, molecular typing
based surveillance, currently existing in the region only as limited scale research
projects.



Characterization of the clones and sporadic isolates clearly shows that
epidemiological fitness is a complex phenomenon and the contribution of
resistance to antibiotics, to disinfectants, and virulence of strains can vary
between clones. An important new observation was that international clones of
E. coli expressed a core type previously rarely encountered. On that basis, we
propose a hypothesis of its role in promoting the emergence of these clones.



In K. pneumoniae the higher rate of increased disinfectant resistance is alarming
among carbapenem resistant isolates, particularly as it was associated with
mobile, plasmid encoded genes. We suggest to start monitoring disinfectant
resistant levels for multi-drug resistant pathogens, at least in regular pointprevalence studies, to be able to warn infection control experts if the situation
deteriorates further.
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The local fosfomycin susceptibility rate of carbapenem resistant K. pneumoniae
was found comparable to those in countries with limited use of the drug. We
strongly recommend to make the parenteral version of this drug available in the
UAE. This should also require testing of susceptibility to fosfomycin in all
hospital laboratories. However, great caution should be exercised using the drug
and it should not be anticipated as to be a single solution to the fast emerging
carbapenem resistant problem in the Gulf region.
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